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ABSTRACT 
 
Cardiovascular diseases are, despite medical advances, the leading cause of death in Western 
countries. At the same time, patients with peripheral arterial disease (PAD) are increasingly older, 
have multiple diseases and are thus increasingly ineligible for conventional revascularization. The 
use of vascular growth factors to induce neovascularization in ischemic tissues - angiogenic gene 
therapy - could possibly offer a new treatment for these no-option patients and could also enhance 
the efficacy of current revascularization techniques.  
 
The aim of this thesis project was to study the safety and the therapeutic potential of vascular 
endothelial growth factors (VEGFs) and platelet derived growth factor B (PDGF-B) separately or in 
combination on inducing functional neovascularization and vessel stabilization after adenovirally 
(Ad) mediated gene transfer (GT) in rabbit and mouse hind limbs. Also, imaging modalities suitable 
for detecting changes at capillary level vessels including ultrasound- and magnetic resonance 
imaging (MRI) and digital subtraction angiography were compared. Additionally, the functionality 
of the induced neovessels was studied using 31phosphorus magnetic resonance spectroscopy (31P-
MRS) and arterial acid-base analyses. Furthermore, factors mediating endogenous collateral growth 
in PAD patients were identified in a retrospective clinical study.  
 
AdVEGF-A GT alone is shown to induce up to 20-fold increase in rabbit hind limb skeletal muscle 
perfusion, leading to the growth of the whole vascular tree, capillary arterialization and improved 
muscle aerobic energy metabolism. Using high-resolution contrast-enhanced ultrasound imaging the 
changes in capillary level vessels were detected non-invasively, in real time and with the accuracy 
approaching the level of histological examination. The benefits of the induced neovessels on muscle 
energy metabolism in ischemic rabbit hind limbs were objectively confirmed using use of 31P-MRS. 
In vivo titration of the dose of AdVEGF-A revealed a relationship between capillary enlargement 
and the metabolic benefits of angiogenic gene therapy, and also displayed the need for dose titration 
in order to avoid gene therapy related side-effects. With the use of an AdVEGF-A+AdPDGF-B 
combination GT the association of pericytes and neovessels is shown to be affected by the site of 
transgene expression. Finally, hemodynamics are shown to have an important role in all vascular 
growth and stabilization mediated by angiogenic gene transfers, and in the formation of endogenous 
collaterals in PAD.   
 
In summary, the therapeutic potential of angiogenic gene therapy has been extensively verified as 
regards to the functionality and structure of induced vessels in animal models. Novel methods, 
suitable for both preclinical and clinical use, have also been tested for imaging microvascular 
growth and studying the functionality of vessels induced by angiogenic gene therapy. It is 
concluded that therapeutic angiogenesis is a promising new treatment option for patients with PAD. 
 
 
National Library of Medicine Classification: QU 107, QY 60.L3, QY 60.R6, QZ 52, WN 185,  
Medical Subject Headings: Diagnostic Imaging; Disease Models, Animal; Gene Therapy; Hindlimb; 
Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Neovascularization, Physiologic; 
Platelet-Derived Growth Factor; Rabbits; Vascular Endothelial Growth Factor A  
Publications G. – A.I. Virtanen Inst .  
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"Life is like a box of chocolates.  
You never know what you're gonna get"  
Forrest Gump  
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ABREVIATIONS 
 
AAV    adeno associated virus 
ABI     ankle brachial index 
Ad    adenovirus 
ALI    acute limb ischemia 
Akt    serine-threonine kinase Akt (PKB) 
Ang    angiopoietin 
AP    alkaline phosphatase 
-sma   -smooth muscle actin 
CAR    coxsackie adenovirus receptor 
CEU    contrast enhanced ultrasound 
CLI    critical limb ischemia 
CT     X-ray computed tomography 
DCE-MRI  dynamic contrast enhanced-magnetic resonance imaging 
DPP    di-peptityl-peptidase 
EC    endothelial cell 
ELISA   enzyme-linked immunosorbent assay 
eNOS   endothelial nitric oxide synthase (NOS III)  
F    French (a unit used to standardize catheter caliber 1 F = 0.33 mm) 
FGF    fibroblast growth factor 
FGFR   fibroblast growth factor receptor 
Flk-1    fetal liver kinase-1 (murine VEGFR-2) 
Flt-1    fms-like tyrosine kinase-1 (VEGFR-1) 
Flt-4    fms-like tyrosine kinase-4 (VEGFR-3) 
G    Gauge (a unit used to measure the diameter of hypodermic needles) 
GM-CSF   granulocyte macrophage-colony stimulating factor 
GT     gene transfer 
HIF    hypoxia inducible factor 
IGF    insulin-like growth factor 
iNOS    inducible nitric oxide synthase (NOS II) 
i.a.    intra-arterial 
i.m.     intra-muscular 
i.v.    intra-venous 
KDR    kinase domain region (human VEGFR-2) 
LacZ    -galactosidase (marker gene) 
MRI    magnetic resonance imaging 
MRS    magnetic resonance spectroscopy 
NO     nitric oxide 
NOS     nitric oxide synthase 
NRP    neuropilin receptor
p    plasmid 
PAD    peripheral arterial disease 
PBS    phosphate buffered saline 
PDGF    platelet derived growth factor 
PDGFR   platelet derived growth factor receptor 
PlGF    placental growth factor  
r     recombinant protein 
SPECT   single photon emission computed tomography 
SMC    smooth muscle cell 
VEGF   vascular endothelial growth factor 
VEGFR   vascular endothelial growth factor receptor 
vp    viral particles 
VPF    vascular permeability factor
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INTRODUCTION 
 
Cardiovascular diseases are the main cause of death in Western countries causing on average almost 
half of the total mortality in Europe. In the forthcoming years the increase in again will inevitably 
further increase the burden of cardiovascular disease (Scholte op Reimer WJM et al., 2006). 
Peripheral arterial disease (PAD) leads to decreased blood flow and ischemia in the lower limbs 
resulting in pain and reduced function (Cotran et al., 1999; Beard, 2000; Norgren et al., 2007). 
Patients with PAD are increasingly older with several co-morbidities. Also, the characteristics of 
the disease have changed making patients with wide-spread changes a challenge to conventional 
revascularization (Kuukasjarvi et al., 1997). Despite medical development, 30 % of critical limb 
ischemia patients still end up with amputation within one year of diagnosis (Norgren et al., 2007). 
Angiogenic gene therapy aims to enhance nature’s own regeneration capacity and may have 
potential in the revascularization of ischemic tissues (Yla-Herttuala and Alitalo, 2003). 
Angiogenesis is a process that includes the growth and branching of vascular structures to form new 
blood vessels and naturally occurs e.g. during growth and wound healing (Risau, 1997). Gene 
therapy means a transfer of nucleic acids into somatic cells of tissues where a beneficial effect can 
be achieved by replacing a missing or non-functioning protein by a functional one (Yla-Herttuala 
and Alitalo, 2003). In angiogenic gene therapy growth factors, such as vascular endothelial growth 
factors (VEGFs), are transferred into ischemic tissues where they stimulate the growth of new blood 
vessels and relieve ischemia (Yla-Herttuala and Alitalo, 2003). Currently, angiogenic gene therapy 
has been extensively tested in both preclinical and clinical trials. Although the initial clinical reports 
were promising, results from randomized, double-blind clinical trials have reported concerns about 
the efficacy of gene therapy (Rissanen and Yla-Herttuala, 2007; Yla-Herttuala et al., 2007) and the 
functionality of newly formed vessels (Richardson et al., 2001; Pajusola et al., 2005). The aim of 
this thesis was to study factors affecting the growth of functional vessels and to test the potential of 
angiogenic gene therapy in the revascularization of ischemic tissues. 
REVIEW OF LITERATURE 
  
 
The blood vascular system and mechanisms of vascular growth 
Organization of the vascular system  
 
The vascular system is the first organ to develop during fetal growth (Risau and Flamme, 1995). 
However, it remains dynamic, responding to changes such as inflammation, ischemia, growth and 
exercise throughout life. Blood flow and perfusion of each tissue are always precisely controlled in 
relation to the needs of the tissue (Guyton and Hall, 2000). Skeletal muscle for example has very 
low perfusion in resting conditions (about 4 ml/min/100g) but can increase perfusion up to 20-fold 
(as high as 80 ml/min/100g) during exercise to meet increased metabolic needs - the greatest 
adaptation of perfusion in the human body (Guyton and Hall, 2000). The regulation of flow and 
perfusion is maintained, besides the regulation of the cardiac function, by the structure of the 
vascular walls and the diameter and number of vessels (Guyton and Hall, 2000). According to 
Poiseuille’s law, the rate of blood flow is directly proportional to the fourth power of the radius of a 
vessel, which demonstrates that the diameter of the vessel plays the greatest role in determining the 
rate of blood flow (Guyton and Hall, 2000).     
 
Arteries carry oxygenated blood from the heart to the periphery with high pressure (fluctuates at 
rest between 80 mmHg and 120 mmHg) and velocity (average during rest: 33 cm/s) (Guyton and 
Hall, 2000). In humans arteries range from several centimeters to 100 m in diameter and have 
strong muscular walls comprising of intimal, medial and adventitial layers separated by internal and 
external elastic laminas (Figure 1) (Cotran et al., 1999). A layer of smooth muscle cells (SMC) in 
the medial layer of the arterial wall generates active contractions that push blood forwards (Guyton 
and Hall, 2000). The SMCs also regulate the diameter of the arteries via constriction or relaxation 
mediated by nitric oxide (NO) released from the endothelium. To initiate a change in vascular 
diameter and blood flow, the endothelium can be stimulated by different factors such as growth 
factors, hormones and also by shear stress (Guyton and Hall, 2000). After branching to smaller 
arteries and further to arterioles (ranging from 100 m to 5 m in diameter), blood pressure and 
velocity in the arterial side are decreased to be more suitable for capillary circulation. A specific 
precapillary sphincter, situated between the end arterioles (metarterioles) and the capillary bed, 
controls the amount of blood going into the capillary level (Guyton and Hall, 2000). 
 
The capillary network consists of fine tubes, 9 to 5 m in diameter, comprising only of an 
endothelial layer and occasional pericytes (Cotran et al., 1999) covering 100 % capillary length but 
only 20 % of the surface area (Figure 1) (DM McDonald, unpublished). Capillaries exchange fluids, 
oxygen, nutrients, electrolytes and hormones with the surrounding tissues via diffusion. To manage 
that, the capillaries need to maintain blood pressure of 10 to 35 mmHg, blood velocity of 
approximately 0.3 mm/s and a tight physical connection with the surrounding cells (Guyton and 
Hall, 2000). Endothelial cells are joined together by tight junctions but small intercellular clefts 
(about 6 to 7 nm in width) between cells are needed for water and water-soluble substances to pass 
through (Guyton and Hall, 2000). In normal conditions, these junctions are just small enough to 
maintain homeostasis without plasma leakage. However, if the endothelial junctions are loosened 
during vascular growth for example or if capillary pressure is increased, albumin is able to leak out 
through these clefts, drive water to the interstitium and cause tissue edema. Also, cellular 
fenestration and increased vesicle transport (vesiculo-vacuolar organelle) have been identified as 
endothelium-based causes for the development of edema (Feng et al., 2000).  
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Post capillary venules (10 to 50 m in diameter), muscular venules (50 to 100 m) and veins (100 
m to several centimeters) conduct oxygen-deprived blood from the periphery back to the heart. 
Veins have thin walls comprising the endothelium, pericytes or SMCs and a loose adventitia 
(Figure 1) (Cotran et al., 1999). The SMCs in veins are less organized than in arteries but still able 
to induce small contractions to support blood flow due to a low, gradually decreasing blood 
pressure that nearly reaches 0 mmHg in the right atrium of the heart (Guyton and Hall, 2000). Other 
mechanisms that maintain the pressure in the venous circulation are: 1) the so called “venous or 
muscular pump” which means that tensing large muscles around the veins, during walking for 
example, pushes blood forwards, 2) venous valves that prevent backflow, and 3) a negative pressure 
caused in the right atrium of the heart during each heart beat. An important feature of the veins also 
is that they are capable of storing large amounts of blood, owing to their dilating potential, and to 
pump the blood back to the circulation if needed (Guyton and Hall, 2000).  
 
          
 
Figure 1. Functional and structural differences of arterial, capillary and venous vessels. The histological 
images have hematoxylin-eosin stainings. 
 
 
Vasculogenesis 
 
The de novo formation of vessels from endothelial precursors, angioblasts, during fetal development 
is called vasculogenesis (Risau and Flamme, 1995). During vasculogenesis fetal stem cells 
differentiate into hemangioblasts which serve as precursors to angioblasts and hematopoietic cells. 
Angioblasts then migrate and differentiate, guided by several growth factors, to form endothelial 
tubes (Figure 2) (Risau and Flamme, 1995). VEGFs have been identified as mediators of angioblast 
migration and differentiation (Risau and Flamme, 1995; Carmeliet et al., 1996). Vasculogenesis via 
bone marrow derived, circulating endothelial precursors has also been suggested to take place 
postnatally (Asahara et al., 1997; Rafii and Lyden, 2003). VEGF, granulocyte macrophage-colony 
stimulating factor (GM-CSF) and other cytokines have been proposed as the mediators of postnatal 
vasculogenesis and especially angioblast activation (Asahara et al., 1999). The current knowledge 
of postnatal vasculogenesis, however, strongly suggests that the bone marrow derived cells do not 
actually incorporate into the endothelium of growing vessels in the adult as during fetal 
development but rather act as sources for growth factors that subsequently stimulate vascular 
growth (Rehman et al., 2003; Purhonen et al., 2008).  
 
 
Angiogenesis 
 
Angiogenesis is a process that includes the growth, branching and reorganization of the primitive 
vascular structures formed by vasculogenesis to form functional vascular networks (Conway et al., 
2001). Types of angiogenesis include sprouting of new vascular branches, enlargement of pre-
existing capillaries and bridging or intussusception of enlarged vessels to form smaller daughter 
vessels (Figure 2) (Risau, 1997; Conway et al., 2001). Loosening of the endothelial cell junctions is 
the first step in angiogenesis. This increases the permeability of the vessel leading to plasma 
extravasation and degradation of the extracellular matrix (Conway et al., 2001). These changes 
allow proliferation of endothelial cells in the vascular wall and their migration to the surrounding 
tissue to form expanding and elongating vascular branches that then form connections to the 
preexisting vascular network. At first, these structures are unstable and leaky but are stabilized by 
the recruitment of accessory cells such as pericytes or SMCs around the vessel. The accumulation 
of pericytes or SMCs inhibits additional endothelial proliferation and the endothelial junctions are 
once more re-established (Conway et al., 2001). The origin of pericytes surrounding the formed 
vessels is yet unclear but on site proliferation and differentiation from endothelial- or mesenchymal 
precursors, stem cells or macrophages have been suggested (Conway et al., 2001). Several 
cytokines mediating angiogenesis have been identified of which the most important are VEGFs and 
fibroblast growth factors (FGFs) (Conway et al., 2001). Angiogenesis is common postnatally for 
example during wound healing, the menstruation cycle in the uterus, and several disease processes 
such as diabetic retinopathy, cancer, ischemic diseases, arthritis and inflammation (Risau, 1997).         
 
Breaking down of endothelial junctions and increasing vascular permeability are crucial for 
efficient angiogenesis (Conway et al., 2001). This process however, can lead to the formation of 
tissue edema via plasma protein extravasation and increased osmotic pressure. Plasma protein 
extravasation does also take place during normal conditions but only so modestly that the lymphatic 
system can easily compensate the changes (Guyton and Hall, 2000). During rapid vascular growth 
the surface area of vessels, perfusion and blood pressure of the vasculature increase so that plasma 
protein extravasation exceeds the capacity of the lymphatic system. Tissue edema has also been 
taken as a hallmark of efficient angiogenesis and in fact it has been shown that the changes in 
capillary size correlate with the increase in endothelial permeability in animal models (Rissanen et 
al., 2003b). However, formation of edema is also a side-effect of angiogenesis that can lead to a 
circulatory collapse or a tissue compartment syndrome (Baumgartner et al., 2000; Callum and 
Bradbury, 2000; Conway et al., 2001). Diuretics and cortisone have been used to treat edema 
(Nauck et al., 1998; Baumgartner et al., 2000) but also means of avoiding it remain an interesting 
field of study. 
 
 
Arteriogenesis
 
Arteriogenesis is a mechanism by which arterial side vascular branches, arterioles, form larger 
conducting arteries (Conway et al., 2001; Schaper and Scholz, 2003). In the adult, arteriogenesis is 
prominently found in ischemic conditions where the formation of collateral arteries is a natural way 
of by-passing vascular blockages (Figure 2) (Schaper and Scholz, 2003). When a conducting artery 
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is blocked the routing of blood flow is changed. Collateral arteries, by-passing the blockage, are 
initially small arterial side branches of the conducting artery. Unlike in angiogenesis, where 
hypoxia is the main activator of vessel growth, in arteriogenesis hemodynamic factors drive vessel 
growth (Schaper and Scholz, 2003). By means of elevated blood pressure and shear stress, caused 
by the blood flow directing to the small arterial branches instead of the blocked main artery, gene 
expression profile in the endothelium of the collateral artery is changed (Schaper and Scholz, 2003). 
Monocyte chemotactic protein (MCP-1) recruits monocytes to the area that is believed to then 
loosen the basement membrane of the arteriole leading to the mobilization of smooth muscle cells 
in the vascular wall (Ito et al., 1997). The mobilization of SMCs is followed by proliferation and 
migration, and changes in the other vascular wall components to increase the diameter of the artery. 
The process continues until the pressure and shear stress are again normalized and the SMCs turn 
back into their constricting phenotype (Hoefer et al., 2001). Stimulation of arteriogenesis in the 
treatment of ischemia is interesting since large collateral vessels could conduct large amounts of 
blood across the blocked main artery (White et al., 1998; Hoefer et al., 2001).  
 
        
Figure 2. Mechanisms of vascular growth. Modified from Conway et al 2001. 
Peripheral ischemic diseases 
Atherosclerosis 
 
Atherosclerosis is a disease process in which lipid, cholesterol-laden macrophages, SMCs, 
connective tissue and calcium-salt precipitates accumulate in the walls of arteries causing 
impairment of blood flow and tissue ischemia most often in the heart, peripheral muscles or in the 
brain (Cotran et al., 1999; Libby, 2002). It is widely accepted that the genetic background, high 
serum LDL and low serum HDL cholesterol levels, high blood pressure, diabetes, smoking, the 
male gender and the lack of physical activity are the main risk factors for atherosclerosis 
(Doevendans et al., 2001; Grech, 2003). Several hypotheses for the pathogenesis of atherosclerosis 
have been presented including the lipid theory, highlighting the role of oxidized LDL, and the 
endothelial injury theory, considering atherosclerosis as a chronic inflammatory response (Ross, 
1999). The development of an atherosclerotic lesion is a stepwise process (Figure 3) that involves 
monocyte adhesion, foam cell formation, SMC proliferation and fibrous cap formation. 
 
   
Figure 3. Development of an atherosclerotic plaque. Based on Cotran et al 1999. 
 
 
Lower limb ischemia 
 
In peripheral arterial disease (PAD) blood flow and subsequently the delivery of oxygen to the 
lower limbs is disrupted resulting in ischemia (Cotran et al., 1999). The prevalence of PAD is about 
3-10 % in the total population (including asymptomatic patients) and is increased by age (15-20 % 
in over 70-year old persons) (Beard, 2000; Norgren et al., 2007). Atherosclerosis is the most 
common cause for PAD and chronic lower limb ischemia. Pain during walking that is relieved by a 
short rest (claudication) is usually the first symptom of lower limb ischemia. Claudication is caused 
by inadequate energy and blood supply to the peripheral muscles during exercise resulting in a 
metabolic acidosis and ischemic pain (Norgren et al., 2007). Diagnostic criteria used to evaluate 
limb ischemia are: maximal walking distance without stopping, loss of peripheral pulses, 
temperature differences, formation of ulcers, rest pain, decreased ankle-brachial systolic blood 
pressure index (ABI) and angiography (Beard, 2000). ABI under 0,5, rest pain or arterial ulcers are 
signs of critical chronic limb ischemia (CLI) that requires immediate medical attention (Norgren et 
al., 2007). Thrombus of an atherosclerotic lesion can lead to an acute worsening of a previous 
chronic disease to acute limb ischemia (ALI) that is presented by acute, severe pain during rest, 
cyanosis and the loss of motor- and sensory functions (Callum and Bradbury, 2000). ALI requires 
revascularization in a few hours to avoid limb loss (Norgren et al., 2007). The classification of PAD 
according to Fontaine, Rutherford and individual clinical signs in different stages of the disease are 
described in Figure 4. 
 
Conventional treatment of chronic lower limb ischemia includes in its early stages lifestyle 
guidance encouraging physical activity, a low fat diet, smoking cessation and good foot care 
preventing formation of ulcers (Norgren et al., 2007). Also, a re-evaluation of pharmaceutical 
treatment of possible high serum LDL, high blood glucose and high blood pressure is needed since 
the risk of death from all cardiovascular causes is increased in patients with PAD. Active treatment 
of diabetes is highly important since the risk of diabetics to develop chronic ulcers is higher than 
that of non-diabetics (Norgren et al., 2007). Low dose, daily acetylsalicylic acid is a basic 
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preventive anti-platelet therapy recommended already at the early stages of PAD (Norgren et al., 
2007). Embolectomy, intra-arterial thrombolytic treatment, percutaneous transluminal angioplasty 
(PTA) and by-pass surgery are the standard treatment options for patients with acutely or critically 
ischemic limbs or a chronic lower limb ischemia that affects the patient’s ability to work. 
Furthermore, ulcers or gangrene need to be treated actively and sufficient pain relief taken care of. 
Also, the use of vasodilators, prostanoids or anticoagulants may benefit some patients (Norgren et 
al., 2007). The incidence of CLI is currently about 500-1000 new cases per year of one million 
people (Norgren et al., 2007). Despite active treatment 30 % of CLI patients will have amputation 
within one year of diagnosis (120-500 amputations/ million/ year) and the mortality during the first 
year after diagnosis among CLI patients is 25 %. Thus, there is a need for the development of 
improved treatment options for both the prevention and treatment of CLI. 
 
 
Figure 4. Classification of PAD by Fontaine and Rutherford, and clinical findings in different stages. PAD 
= peripheral arterial disease, CLI = critical chronic limb ischemia, ALI = acute limb ischemia. Based on 
Norgren et al 2007. 
  
 
Growth factors and receptors 
 
 
Vascular endothelial growth factors and their receptors 
The first member of the VEGF family, VEGF-A, was discovered in 1989 by two independent 
research groups describing a factor that stimulated the growth of endothelial cells (Leung et al., 
1989; Ferrara and Henzel, 1989). However, already in 1983 a cytokine stimulating endothelial 
migration and vascular growth, called vascular permeability factor (VPF), had been described 
(Senger et al., 1983) and was in 1989 indentified the same growth factor than the newly purified 
VEGF-A (Keck et al., 1989). Human VEGF-A is currently known to have eight different splice 
forms consisting of 121, 145, 162, 165, 165b, 183, 189 or 206 amino acids (Tischer et al., 1991; 
Houck et al., 1991; Poltorak et al., 1997; Jingjing et al., 1999; Bates et al., 2002; Lange et al., 
2003). VEGF-A121 is acidic and thus freely soluble in the extracellular matrix. The other VEGF-A 
isoforms are increasingly basic, depending on their number of amino acids, insoluble and bound to 
the extracellular matrix and heparan sulphate on cell surfaces (Ferrara, 2004). The matrix-binding 
properties of VEGF-A have been shown critical for the formation of proper vascular networks 
(Carmeliet et al., 1999; Ruhrberg et al., 2002). VEGF-A165 has intermediate matrix-binding 
properties and is the principal effector of VEGF-A actions (Ferrara, 2004). VEGF-A is a regulator 
of angiogenesis, arteriogenesis, vasodilatation and vascular permeability but is also associated with 
stem cell mobilization, monocyte chemoattraction, osteoblast-mediated bone formation and 
neuronal protection (Storkebaum et al., 2004; Ferrara, 2004). VEGF-A is indispensable for growth; 
the lack of only one VEGF-A allele leads to embryonic lethality due to defects in the formation of 
the vascular system (Carmeliet et al., 1996; Ferrara et al., 1996). In the adult VEGF-A is expressed 
widely in several organs and in many different cell types with low levels that for example in the 
vascular endothelium serve as survival factors for ECs (Gerber et al., 1998a; Gerber et al., 1998b). 
The expression of VEGF-A is tightly regulated and it is up-regulated by hypoxia but also by other 
growth factors and by vascular shear stress (Rissanen et al., 2002; Ferrara, 2004). VEGF-A levels 
lower than normal are associated with pre-eclampsia and postnatal respiratory distress syndrome, 
whereas overly high levels of VEGF-A have been associated with for example tumor growth, 
ascites formation, brain edema, polycystic ovary syndrome, macular generation and diabetic 
retinopathy (Ferrara, 2004).  
 
VEGF-B, the second member of the VEGF family, was discovered in 1996 (Olofsson et al., 1996a). 
It is found in two isoforms, VEGF-B167 and VEGF-B186 (Olofsson et al., 1996b). VEGF-B is 
expressed in the heart, skeletal muscle and in the SMCs of large arteries together with VEGF-A 
(Olofsson et al., 1996a). The specific biological role of VEGF-B is currently under active research. 
Initially it was reported to regulate the proliferation of endothelial cells (Olofsson et al., 1996a). 
Later, knockout studies showed that VEGF-B-/- mice, although viable, have developmental defects 
in their hearts and coronary vasculature, and they also recover less efficiently from myocardial 
ischemia than wild type animals (Bellomo et al., 2000). VEGF-B has also been suggested to have a 
role in pathological angiogenesis (Mould et al., 2003). VEGF-B has been found essential for the 
normal function of the heart but not for the development of the cardiovascular system or 
angiogenesis in the skeletal muscle of an adult (Aase et al., 2001). The most recent evidence 
indicates that VEGF-B would have a myocardial specific role in post natal angiogenesis (Li et al., 
2008; Lahteenvuo et al., 2009).   
 
VEGF-C was cloned in 1996 (Joukov et al., 1996) and shares high similarity in structure and 
binding with VEGF-D that was found in 1997 (Yamada et al., 1997). Both VEGF-C and -D are 
synthesized in long precursor forms that can then go through proteolytic processing to yield mature 
(NC) forms (Joukov et al., 1997; Stacker et al., 1999). The unprocessed forms of VEGF-C and -
D bind VEGF-receptor (VEGFR) 3 stimulating lymphatic growth, where as the processed forms 
also bind with high affinity to VEGFR-2 and stimulate angiogenesis as well as growth of lymphatic 
vessels (Joukov et al., 1996; Stacker et al., 1999; Rissanen et al., 2003b). During embryonic 
development VEGF-C is expressed in areas of lymphatic sprouts and is essential for lymphatic 
vessel development (Karkkainen et al., 2004). In contrast, VEGF-D is expressed more widely 
during development e.g. in limb buds, the heart and several other organs implicating a more diverse 
developmental role (Avantaggiato et al., 1998). In the adult, VEGF-C is expressed, besides the 
lungs, heart and kidneys, abundantly in lymph nodes (Lymboussaki et al., 1999) and also in 
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neuroendocrine cells of pancreas and thymus (Partanen et al., 2000). VEGF-D is expressed in the 
heart, skeletal muscle, lungs, colon, small intestine and in SMCs of normal and atherosclerotic 
arteries (Achen et al., 1998; Rutanen et al., 2003). Additionally, both VEGF-C and -D have reported 
to be up-regulated in several tumors and have been suggested to have a role in tumor invasion and 
metastasis (Karpanen et al., 2001; Skobe et al., 2001; Stacker et al., 2001; Saharinen et al., 2004). 
Neutralization of both VEGF-C and -D by a VEGFR-3 antibody has led to decreased 
lymphangiogenesis and lymph node metastasis in a mouse tumor model (He et al., 2002).  
 
VEGF-E and -F are collective names for growth factors derived from Orf-viruses (Lyttle et al., 
1994; Ogawa et al., 1998) and snake venom (Yamazaki et al., 2005), respectively. The VEGF-Es 
are only partly similar to VEGFs found in mammals and their receptor binding and biological 
effects differ (Wise et al., 1999). Overall, VEGF-Es are not bound to heparan sulphate and thus 
soluble in the matrix. One VEGF-E form has been reported to stimulate vascular growth without 
increasing vascular permeability (Kiba et al., 2003). VEGF-Fs consist of the VEGF -domain, bind 
VEGFR-2 and have been described to block the activity of VEGF-A165 (Yamazaki et al., 2003; 
Yamazaki et al., 2005). The therapeutic potential of these growth factors is currently unknown.  
 
Placental growth factor (PlGF) was first characterized in 1991 (Maglione et al., 1991). It is found in 
four isoforms, PlGF1-4 consisting of either 149 (Maglione et al., 1991), 170 (Maglione et al., 
1993), 221 (Cao et al., 1997) or 252 amino acids (Yang et al., 2003), respectively. The isoforms 
differ in their solubility; PlGF-1 and PlGF-3 do not bind to heparin where as PlGF-2 and PlGF-4 are 
heparin-binding. PlGF is naturally expressed in the blood vessel endothelium in the human placenta 
during pregnancy, and a drop in placental PlGF levels is associated with pre-eclampsia (Yang et al., 
2003). However, knockout studies have not revealed any pathological changes, infertility or 
premature death in PlGF-/- animals, implicating that PlGF would not be necessary for normal 
development or for pregnancy (Carmeliet et al., 2001). These studies have shown however that in 
pathological conditions such as cancer, ischemia, inflammation or wound healing the lack of PlGF 
results in improper angiogenesis (Carmeliet et al., 2001). Over-expression of PlGF either in 
adulthood or during development has been shown to induce angiogenesis, vascular permeability and 
formation of vascular glomeruloid structures via up-regulation of VEGF-A (Odorisio et al., 2002; 
Oura et al., 2003; Lahteenvuo et al., 2009). Additionally PlGF stimulates migration and 
differentiation of bone marrow derived monocytes and hematopoietic cells (Hattori et al., 2002; 
Pipp et al., 2003). 
 
The VEGF family growth factors have five receptors: VEGFR 1-3 (de Vries et al., 1992; Terman et 
al., 1992; Pajusola et al., 1992; Galland et al., 1992) and neuropilin receptors (NRP) 1-2 (Soker et 
al., 1998; Gluzman-Poltorak et al., 2000). The VEGFR-1-3 are tyrosine kinase receptors and are 
found in ECs and bone marrow derived cells (Ferrara, 2004). The NRPs are trans-membrane 
receptors and are present, besides the vascular wall, in neurons (Giger et al., 1998). The receptors 
also have soluble forms such as sVEGFR-1, sVEGFR-2, sNRP-1 and sNRP-2 that function as 
extracellular decoy receptors and regulate free growth factor concentration (Kendall and Thomas, 
1993; Neufeld et al., 2002; Ebos et al., 2004). VEGFR-1 is a debated receptor. It binds VEGF-A, -B 
and PlGF and is reported to mediate endothelial-, hematopoietic cell- and monocyte chemotaxis 
(Luttun et al., 2002; Pipp et al., 2003). Some studies suggest that VEGFR-1 would not be able to 
induce signaling on its own but would rather act as an decoy receptor for VEGFR-2-activating 
ligands (Ferrara, 2004). Others report that VEGFR-1 enhances signaling via VEGFR-2 (Autiero et 
al., 2003). The soluble VEGFR-1 has been claimed to have a role, besides only being a decoy 
receptor, in the guidance and lodging of endothelial cells (Orecchia et al., 2003). VEGFR-2 
mediates most of the angiogenesis and vascular permeability effects of VEGFs and is indispensable 
for growth (Shalaby et al., 1995; Rissanen et al., 2003b; Ferrara, 2004). It binds VEGF-A, VEGF-
Es, VEGF-Fs and both the mature and unprocessed forms of VEGF-C and -D (Yla-Herttuala et al., 
2007). VEGFR-3 binds both the mature and unprocessed forms of VEGF-C and -D and mediates 
lymphangiogenesis and lymphatic vessel survival (Makinen et al., 2001). NRP-1 binds VEGF-A, -
B, -E and PlGF. Traditionally, NRP-1 is believed to have a function only as an amplifier of the 
signaling via VEGFR-2 with respect to angiogenesis (Soker et al., 1998; Ferrara, 2004) but some 
reports have also indicated that it might have a role alone as an activator of EC migration and 
survival (Wang et al., 2003; Wang et al., 2007). NRP-2 binds VEGF-A, -C and -D and is currently 
thought to have a role in the formation of small lymphatics and capillaries (Yuan et al., 2002; 
Karpanen et al., 2006). The functions and binding properties of VEGFs and their receptors are 
summarized below in Figure 5.  
 
 
Figure 5. Binding of the VEGF family proteins to their receptors. Modified from Rissanen et al 2007. 
 
 
Platelet derived growth factors and their receptors 
Platelet derived growth factor (PDGF) was first identified in the 1970s (Ross et al., 1974; Heldin et 
al., 1979; Antoniades et al., 1979). Currently, the PDGF family of proteins consists of four 
members: PDGF-A (Heldin et al., 1979; Deuel et al., 1981; Bonthron et al., 1988), -B (Collins et 
al., 1985), -C (Li et al., 2000) and -D (Bergsten et al., 2001; LaRochelle et al., 2001), from which 
five dimeric forms: -AA, -AB, -BB, -CC, -DD have been described so far. PDGF-A is found in 196 
and 211 amino acid containing splice forms, PDGF-B is 241 amino acids long, and PDGF-C and 
PDGF-D have 345 and 370 amino acids, respectively (Fredriksson et al., 2004). The PDGFs 
promote the proliferation of several types of cells with mesenchymal origin, such as fibroblasts and 
smooth muscle cells, and also promote cell migration and survival (Tallquist and Kazlauskas, 
2004). In the adult, PDGFs are widely expressed in most human tissues. PDGF-A has the highest 
expression in the heart, pancreas and skeletal muscle, PDGF-B in the heart and placenta, PDGF-C 
in the heart, kidneys, pancreas and the liver, and PDGF-D in the heart, pancreas and the ovaries 
(Fredriksson et al., 2004). All PDGFs have been described to have angiogenic potential but due to 
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their specificity on SMCs and pericytes the PDGFs are likely to contribute mostly in the angiogenic 
process to vascular stabilization. The PDGFs signal via binding to PDGF receptors  and  
(PDGFR- and -) (Heldin et al., 1988) that also form dimers (,  and ) (Fredriksson et al., 
2004). Both PDGFRs are required during development (Tallquist and Kazlauskas, 2004). PDGFR- 
is involved in the stimulation of several cell types including chondrocytes (Soriano, 1997), 
oligodentrocytes (Fruttiger et al., 1999), and kidney (Li et al., 2000) and dermal (Karlsson et al., 
1999) mesenchyme. PDGFR- mostly regulates the fate of vascular smooth muscle and pericytes 
(Soriano, 1994; Lindahl et al., 1997). The functions and binding properties of PDGFs and PDGFR 
are summarized in Figure 6. 
 
 
 
Due to their binding ability to PDGFR- and stimulation of vascular SMCs, PDGF-B and -D are 
interesting candidates for the stabilization of vessels induced by gene therapy. Endothelial-targeted 
PDGF-B and VEGF-A combination gene transfers have been reported to improve vascular wall 
maturation and duration of angiogenic effects (Richardson et al., 2001; Levanon et al., 2006). 
Endothelial PDGF-B retention has been demonstrated crucial for the formation of proper PDGF-B 
gradients and investment of pericytes on vessels (Lindblom et al., 2003; Bjarnegard et al., 2004). 
Accordingly, non-endothelial expression of PDGF-B in tumors has been reported to have caused 
pericyte detachment (Abramsson et al., 2003). Up-regulation of FGF-2 and the stimulation of FGF-
receptor 1 have been shown to mediate PDGF-B induced SMC proliferation (Millette et al., 2005) 
and also FGF-2 and VEGF-A have been shown to induce PDGF-B expression and PDGFR- 
activation (Kano et al., 2005). 
 
 
Other angiogenic factors  
 
Angiopoietins (Ang) are a group of growth factors implicated in remodeling and maturation of 
vasculature and are thus of interest to angiogenesis researchers (Davis et al., 1996; Thurston et al., 
1999; Hawighorst et al., 2002). The Ang family consists of Ang-1 and -2 that bind Tie-1 and -2 
receptors (Davis et al., 1996; Maisonpierre et al., 1997). However, current knowledge of the 
angiopoietins is largely controversial and thus the potential of the growth factors in angiogenic gene 
therapy is unclear. Binding of Ang-1 to Tie-2 is potentially interesting as it has been reported to 
mediate EC survival and the remodeling and stabilization of vasculature (Davis et al., 1996; 
Figure 6. PDGFR ligands 
and functions. Modified 
from Fredriksson et al 2004.
Thurston et al., 1999; Papapetropoulos et al., 2000; Hawighorst et al., 2002). However, Ang-1 has 
also been reported both to stimulate (Shyu et al., 1998; Suri et al., 1998; Chae et al., 2000) and 
suppress (Visconti et al., 2002) angiogenesis, and both to promote (Shim et al., 2002) and inhibit 
(Hawighorst et al., 2002) tumor growth. Ang-2 is most often described as a natural antagonist of 
Tie-2 leading to endothelial apoptosis and disruption of angiogenesis (Maisonpierre et al., 1997; 
Lobov et al., 2002). However, in some reports, Ang-2 has also been implicated as a cell type 
specific Tie-2 agonist (Gale et al., 2002) and in the presence of VEGF-A to stimulate sprouting 
angiogenesis (Lobov et al., 2002).  
 
One of the most potent growth factors to induce angiogenesis besides the VEGFs is fibroblast 
growth factor (FGF) -4 (Rissanen et al., 2003a). The FGF family currently consists of 23 members 
(Yla-Herttuala and Alitalo, 2003) of which FGF-1, -2, -4 and -9 are described the most potent 
mitogens in vitro (Ornitz et al., 1996). Of these, at least FGF-2 has been reported to up-regulate 
VEGF-A expression and angiogenesis induced by FGF-2 can be inhibited by VEGFR-2 antagonism 
(Stavri et al., 1995; Tille et al., 2001). The FGFs bind five distinct receptors, namely FGFR-1-5, of 
which the fifth one is likely a decoy receptor due to a lack of a tyrosine kinase domain (Sleeman et 
al., 2001; Murakami and Simons, 2008). The stimulation of many cell types including both ECs and 
SMCs, has been described beneficial for the angiogenic properties of FGFs (Ornitz et al., 1996; 
Yablonka-Reuveni et al., 1999). The FGFs are involved in embryonic development, tissue 
regeneration, cell transformation, tumor growth and angiogenesis (Murakami and Simons, 2008).    
 
Other growth factors that have been described to have angiogenic potential are for example 
hepatocyte growth factors (HGF) and granulocyte macrophage colony stimulating factor (GM-CSF) 
(Rissanen and Yla-Herttuala, 2007). HGF has been reported to induce angiogenesis at least partially 
mediated by VEGF-A up-regulation (Dong et al., 2001). Additionally, transcription factors such as 
hypoxia inducible factor (HIF) -1, and nitric oxide synthases (NOS) have been described to 
contribute to angiogenesis. HIF-1 is a factor, strongly up-regulated during acute ischemia, that can 
activate the transcription of several VEGF-A isoforms and has thus been suggested to stimulate 
more physiological angiogenesis than a gene transfer of a single VEGF-A isoforms (Pajusola et al., 
2005). Adenoviral eNOS has been described to induce vasodilatation and to increase perfusion of 
ischemic tissues (Brevetti et al., 2003) but its therapeutic potential with respect to effects on 
endothelial proliferation and the stability of the vessels remains unclear (Cooney et al., 2006).  
Gene therapy for vascular growth 
 
 
Principles of gene therapy  
 
The current treatments for cardiovascular diseases are based on prevention and revascularization of 
the blockages in the main conducting arteries (Norgren et al., 2007). It is, however, common that 
patients have wide-spread changes that propose a challenge for conventional revascularization 
approaches (Kuukasjarvi et al., 1997). Gene therapy is a promising tool for revascularization 
through the stimulation of growth of the whole vascular tree, including large conducting arteries, 
veins and capillary level vessels (Rissanen and Yla-Herttuala, 2007; Yla-Herttuala et al., 2007). The 
process by which new blood vessels are grown is called therapeutic angiogenesis. In gene therapy a 
gene construct, encoding a therapeutic protein, is transferred into somatic target cells by a process 
called transduction (Watson et al., 1992). In the target cells the gene construct causes the expression 
of the therapeutic protein in the target tissue. If the produced protein is secreted, it can then 
stimulate, depending on the protein, for example the growth of blood vessels in the surrounding 
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tissue. The efficacy of gene therapy is dependent on the success of all the following: 1) the delivery 
of the gene construct to the target tissues and target cells, 2) the efficacy of the gene construct to 
produce the therapeutic protein, 3) the duration of protein expression, 4) the solubility of the 
therapeutic protein and 5) the biological potency of the therapeutic protein as with respect to the 
receptors and intra-cellular signaling needed to mediate the therapeutic effect (Yla-Herttuala and 
Alitalo, 2003; Rissanen and Yla-Herttuala, 2007).     
 
 
Gene transfer methods 
 
In its ideal form, the gene therapy product could be administered systemically and the gene 
construct could find its way to the place where it is needed. Unfortunately, systemic administration 
usually has a high incidence of side-effects and thus the gene construct needed to be guided to the 
right destination (Hiltunen et al., 2000). In theory, this can be achieved by targeting the construct, 
by modifications of vector-receptor interaction or for example by a hypoxia-sensing element that 
then regulates the binding of the construct so that it can only bind to hypoxic areas (Wickham, 
2000). In preliminary studies using targeted constructs, however, transduction efficacies have been 
decreased by the modifications to the construct (Rissanen and Yla-Herttuala, 2007). Other reasons 
for low efficacy of intra-vascular gene transfers are the dilution of the construct in the systemic 
circulation and the fact that the ischemic areas are by definition out of reach of the circulation and 
thus the construct can possibly only reach some of the hypoxic border areas but not the ischemic 
core (Rissanen and Yla-Herttuala, 2007). Thus, injections of gene constructs to target tissues are to 
date the most efficient gene transfer methods (Yla-Herttuala et al., 2007). Injections through the 
skin to skeletal muscle is the most convenient method used for the stimulation of vascular growth in 
lower limb ischemia (Yla-Herttuala and Alitalo, 2003; Rissanen and Yla-Herttuala, 2007). Catheter 
mediated injections to the myocardium can be used in myocardial ischemia (Sylven et al., 2002). 
Whereas intramuscular injections yield more widespread effects needed in the revascularization of 
ischemic tissues, targeted, local delivery to the vascular wall can be desirable, for example in the 
prevention of restenosis or in the stimulation of collateral artery growth. For that purpose special 
catheters and gene product containing, vessel surrounding capsules (collars) have also been 
developed to deliver the virus into the vascular wall without losing it to the systemic circulation 
(Laitinen et al., 1997). In “ex vivo” gene transfers cells from the target tissue are collected, 
cultivated in cell culture and transduced in the laboratory. The transduced cells are then returned to 
the target tissue and only they will contain the gene product and secrete the therapeutic protein 
(Cavazzana-Calvo et al., 2000). However, the “ex vivo” approach is highly laborious and thus the 
method is likely not suitable for clinical applications requiring immediate action.   
 
 
Gene transfer vectors 
To achieve an efficient delivery of the gene product to the target tissue, a gene delivery vehicle, a 
vector, is needed (Yla-Herttuala and Alitalo, 2003). Vectors can be divided into viral vectors and 
non-viral vectors based on their biological background, and the viral vectors can be further divided 
into integrating and non-integrating vectors depending on their ability to integrate into to the host 
cell genome. The type of vector used partly determines the efficacy of the gene transfer and how 
long the gene product will be expressed in the target cells. An ideal vector efficiently delivers the 
gene product into the target cells and also assists in nuclear transport. Long-term expression is 
achieved by the integration of the gene product into the host cell genome, where as a short-term 
expression is a result of an extra-chromosomal placement. Some modified viral vectors can, 
however, also yield relatively long expression by division in the extra-chromosomal position using 
their own reproduction genes (Grieger and Samulski, 2005). Long gene expression can be useful in 
cases where the depletion of a protein is treated with a gene product producing a replacement 
protein such as in X-scid (Cavazzana-Calvo et al., 2000). However, a long-term expression can also 
be harmful, for example in the case of stimulation of vascular growth that could possibly contribute 
to tumor growth or macular degeneration (Yla-Herttuala and Alitalo, 2003; Ferrara, 2004). 
Integration of the gene product into the host genome can also result in insertional mutagenesis and 
activation of malignancies (Hacein-Bey-Abina et al., 2003). 
   
Table 1. Characteristics of the most common gene transfer vectors  
Vector Advantages Disadvantages 
Non-viral vectors 
(plasmids, oligonucleotides 
and their modified 
complexes) 
Safe                                            
Easy to produce 
Poor efficacy                       
Very short expression  
Adenoviruses High transduction efficacy         
Easy to produce                    
High titers                 
Transduces both proliferative 
and quiescent cells                    
Does not integrate to genome 
Transient expression (~two     
weeks)                              
Inflammatory reactions          
Immunity towards the virus 
(repeated administration 
requires another serotype) 
Adeno-associated viruses 
(AAV) 
Long-term expression          
Tropism towards specific 
tissues (skeletal muscle, 
myocardium) 
Difficult to produce in high 
titers                                           
Expression duration currently 
unknown                           
Safety data conflicting 
Retroviruses Stable gene expression Non-specific integration to the 
genome - possibility for 
induction of malignancies 
Transduces only dividing cells 
Low efficacy                      
Difficult to produce in high 
titers 
Lentiviruses Stable gene expression 
Transduces both proliferative 
and quiescent cells           
High DNA-capacity 
Non-specific integration to the 
genome                          
Difficult to produce in high 
titers                                     
Poor efficacy in other than 
hematopoietic cells 
Modified from Rissanen et Ylä-Herttuala 2007. 
 
Modified adenoviruses are the most frequently used and most effective vectors to date 
(http://www.wiley.co.uk/genetherapy/clinical/). They have a high transduction efficacy and are 
relatively easy to produce even in high concentrations (Kovesdi et al., 1997; Raty et al., 2008). 
Adenoviruses are DNA-viruses that can carry up to 30 kb of DNA (gutless vectors) and can 
transfect both dividing and non-dividing cells (Kovesdi et al., 1997). Gene expression length after 
adenoviral transduction is about 1-2 weeks (Muruve, 2004; Korpisalo P et al., 2007). The gene 
construct remains non-dividing in an extra-chromosomal position and is destroyed among the cell 
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cycle and by the immune system. Accordingly, the greatest weakness of adenoviruses as vectors is 
related to the immune response they elicit (Muruve, 2004). In nature they cause respiratory 
infections and thus many people might already have antibodies against them. Formation of 
antibodies destroys the virus immediately and that is why a repeated administration of the virus 
using a same serotype does not lead to sufficient transduction (Muruve, 2004; Korpisalo P et al., 
2007). Adenoviruses enter the cells using coxsackie-adenovirus receptors (CAR) and integrin 
receptors whose expressions partly determine the transduction efficacy of the virus (Wickham et al., 
1993; Bergelson et al., 1997). CARs are highly expressed in the respiratory epithelial cells, 
cardiomyocytes and hepatocytes, whereas in skeletal muscle the amount of CAR is limited in other 
than regenerating myofibers (Bergelson et al., 1997). Modification of the capsid proteins of 
adenoviruses might improve its transduction efficacy in skeletal muscle but the results remain to be 
seen (Wickham, 2000). Adjusting the transcription efficacy by special tissue specific promoters has 
also been suggested (Fadel et al., 1998; Hiltunen et al., 2000; Wickham, 2000; Laurema et al., 
2003). The characteristics of adenoviruses in comparison to other viral and non-viral vectors are 
described in Table 1. 
 
 
Preclinical experiments
 
The purpose of preclinical experiments is to find out the safest and most efficient gene products for 
clinical testing. Both in vitro and in vivo tests have an important role in preclinical testing of gene 
therapy. In vitro cell culture tests allow the investigation of mechanism of action and verification of 
gene product functionality without confounding effects of e.g. the immune system or injection 
trauma. However, the cell culture experiments cannot at least yet mimic the complexity of organ 
systems and thus the in vivo animal experiments are crucial. 
 
The existence of factors inducing vascular growth (tumor angiogenesis factor) was identified 
already in 1939 when the relationship of vascular growth and tumors was studied (Ide et al., 1939). 
In the 1970s it was discovered that factors inducing endothelial proliferation could also be used to 
grow new blood vessels in a therapeutic way (Folkman, 1971; Svet-Moldavsky and Chimishkyan, 
1977). For limb ischemia gene transfers (GTs) were first tested in 1992 when bFGF recombinant 
protein was injected into a rabbit hind limb after an ischemia operation (Baffour et al., 1992). 
Ischemia operations have since been an important part of preclinical tests and models have been 
developed for all small rodents. The use of small rodents is more cost effective than the use of 
rabbits for example, but the results are compromised by the small muscle mass and the difficulty of 
the operations due to extremely small proportions (Rissanen and Yla-Herttuala, 2007). Importantly, 
also the well-being of the animals has been considered and the models have been developed into 
less traumatic (Rissanen et al., 2003a). Unfortunately, findings from only ischemic tissues may have 
some over-interpretation as acutely ischemic tissues yield very high levels of endogenously up-
regulated growth factors (Rissanen et al., 2002). Thus, the studies should be performed also in 
normoxic muscles to be able to separate the effects of endo- and exogenous factors (Rissanen and 
Yla-Herttuala, 2007). Many other models besides the hind limb ischemia model have also been used 
to study angiogenesis, to mention few: cardiac models (Rutanen et al., 2004), a mouse ear model 
(Frank et al., 1994), a tracheal model (Baluk et al., 2005), zebra fish and tadpole models (Ny et al., 
2006) and a normoxic hind limb model (Rissanen et al., 2003b). These models do not necessarily 
give information needed for the treatment of an ischemic leg of a patient but they do provide 
important information on the mechanisms of vascular growth and the structure of the formed 
vascular systems with fewer confounding factors and less harm to the animals as compared to the 
ischemia models. In addition to the acute ischemia models, the induction of chronic ischemia has 
been pursued in order to better resemble human chronic ischemia with less endogenous growth 
factor stimulation (Baffour et al., 2000). However, these models suffer from high variation. The use 
of genetic models is also an important achievement to make animal models better mimic the human 
disease. Diabetes and hypercholesterolemia, factors often associated with human lower limb 
ischemia, have for example been induced in animals (Roy et al., 2006; Heinonen et al., 2007).  
 
To date several genes have been tested for their therapeutic potential for vascular growth in animal 
models. The most investigated and also the most potent angiogenic growth factors have shown to be 
VEGFs and FGFs. They have also been the only ones reported to have induced efficient capillary 
enlargement (Pettersson et al., 2000; Rissanen et al., 2003a; Rissanen et al., 2003b; Ozawa et al., 
2004). In contrast, sprouting angiogenesis has been described more often and in relation to several 
different growth factors such as PDGFs (Cao et al., 2002; Li et al., 2003), Ang-1 (Shyu et al., 
1998), HGFs (Toyoda et al., 2001) and insulin-like growth factors (Su et al., 2003). Interestingly, 
HGF, IGF-1, PDGF-B, PlGF and FGFs have all been shown to at least partially mediate their 
angiogenic effects via VEGF-A up-regulation (Ferrara, 2004; Yla-Herttuala et al., 2007). Tissue 
edema, a side-effect of efficient angiogenic gene therapy and also a marker of efficient vascular 
growth, has been described after VEGFs and FGFs (Pettersson et al., 2000; Rissanen et al., 2003a; 
Rissanen et al., 2003b; Rutanen et al., 2004). There are also reports of presumably efficient 
angiogenesis without edema formation (Kiba et al., 2003; Pajusola et al., 2005; Zheng et al., 2006) 
but these results might be compromised by the fact that in small rodents the detection of moderate 
edema is very difficult. Recently, combination GTs with VEGFs or FGFs and PDGFs or 
angiopoietins have become an interesting target to reduce edema associated with angiogenic gene 
therapy and to improve the maturity and stability of induced vessels (Richardson et al., 2001; Hao et 
al., 2007). The unsolved issues regarding angiogenic gene therapy in the preclinical experiments 
still are: 1) Stability of vessels - chronic ischemia models have been difficult to develop and thus 
the results from long-term time points are often inconclusive. 2) Is there a need for long-term 
expressing vectors or is a short up-regulation of growth factors enough to induce the growth of 
functional vessels? 3) Are the induced vessels metabolically active? 4) How to avoid the formation 
of edema? 5) Are gene combinations more potent and more physiological than an administration of 
a single growth factor?        
Clinical trials 
 
The first clinical attempt for the treatment of lower limb ischemia with gene therapy was performed 
in 1996 when an intravascular plasmid (p)VEGF-A165 GT was reported to induce an improved 
blood flow to an ischemic area (Isner et al., 1996). Edema was then detected as a side-effect of the 
therapy (Isner et al., 1996). Promising angiographic results, improved ABI, improved blood flow 
and healing of ischemic wounds were also found in phase I studies in 1998 after pVEGF-A165 GT 
(Baumgartner et al., 1998; Isner et al., 1998; Baumgartner et al., 2000). However, none of these 
studies had placebo controls and thus the results remained inconclusive. Trials with adenoviruses 
also yielded initially promising results with the therapy being well tolerated and patients only 
showing slight fever (Makinen et al., 2002; Rajagopalan et al., 2002). Overall, angiogenic gene 
therapy has been well tolerated and safe in clinical trials with no evidence of malignancies related to 
the gene product (Yla-Herttuala and Alitalo, 2003). However, looking beyond lower limb ischemia 
trials one death has been associated with a high dose of adenovirus in an immunoincompetent 
patient (Lehrman, 1999). In the past few years data from the randomized, controlled, phase II/III 
trials have emerged. Most limb ischemia trials with naked plasmid failed to reach their goals 
(Rissanen and Yla-Herttuala, 2007), except the TRAFFIC-study that reported an increase in peak 
walking time in patients that received intra-arterially administered FGF-2 as compared to placebo 
controls (Lederman et al., 2002). Most studies with adenoviruses have also been negative (Rissanen 
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and Yla-Herttuala, 2007) and only VEGF-A165 has been reported efficient (Makinen et al., 2002). In 
the treatment of myocardial ischemia, phase II/III studies have yielded slightly more positive results 
but only with AdVEGF165 (Hedman et al., 2003), pVEGF-A165 (Kastrup et al., 2005), AdVEGF121 
(Stewart et al., 2006) and AdFGF-4 (Grines et al., 2003). Low efficacy of the gene constructs for 
angiogenesis, too short expression of the gene product to result in efficient vascular growth, low 
tissue concentrations of the gene products, inefficient gene delivery routes, poorly designed time 
points with respect to the duration of gene expression and highly subjective end-points such as 
treadmill tests and the evaluation of pain relief have been suggested among the reasons for the vast 
failures in the randomized controlled trials (Rissanen and Yla-Herttuala, 2007). 
 
 
Imaging vascular growth 
 
As the effects of angiogenic gene therapy take place mostly at the capillary level vessels, the 
imaging of capillary level circulation is crucial to demonstrate the efficacy of the treatment. None of 
the current noninvasive perfusion measurement techniques, such as dynamic contrast enhanced 
steady-state magnetic resonance imaging (DCE-MRI), x-ray computed tomography (CT), single 
photon emission computed tomography (SPECT), laser Doppler, and power Doppler based 
ultrasound techniques, can provide simultaneous capillary level imaging at a high frame-rate, good 
penetration, efficient contrast agent separation from background tissue, and a contrast agent that is 
retained in leaky angiogenic vessels. DCE-MRI offers relatively good sensitivity and spatial 
resolution in vascular imaging, the possibility to perform whole organ scans, as well as functional 
imaging (Miller et al., 2005). However, in DCE-MRI perfusion imaging, much of the spatial 
resolution must be sacrificed to get a sufficient frame rate for bolus tracking. Moreover, MRI 
devices are not widely accessible to experimental researchers. Although highly sensitive, SPECT 
suffers from poor spatial resolution (Miller et al., 2005). Micro-CT is suitable for very accurate (up 
to 5 m) postmortem anatomical vascular imaging but the protocols for dynamic studies in vivo are 
less well established, in addition to well known drawbacks of ionizing radiation and the low 
sensitivity of CT to contrast agents. Laser Doppler and optical imaging methods suffer from low 
resolution and poor tissue penetration (Miller et al., 2005).  
 
Contrast enhanced ultrasound (CEU) is increasingly used for perfusion measurement in various 
tissues including human skeletal muscle (Krix et al., 2005). One of the most interesting, novel 
aspects of ultrasound imaging is the use of microbubble contrast agents (large, >1 m 
microbubbles) that not only remain in circulation despite vessel leakiness (Orden et al., 2003; Miller 
et al., 2005) but can also have antibodies attached to their surface, allowing the possibility of 
imaging at molecular level (Ellegala et al., 2003). Previously it has been shown that the backscatter 
signal from microbubbles correlates in a linear manner with the concentration of bubbles in silico 
and in vitro as well with blood flow in vivo according to the classical tracer-dilution theory 
(Cosgrove et al., 2001; Galbraith et al., 2002; Thijssen and de Korte, 2005). Contrast enhanced 
ultrasound (CEU) with Power Doppler has been validated in skeletal muscle perfusion measurement 
both in animals and humans (Arsic et al., 2003; Krix et al., 2005). However, power Doppler based 
ultrasound techniques, although they have good penetration and high frame rates, lack in their 
ability to separate contrast agent and tissue signals from each other and are also highly affected by 
movement artifacts. Contrast pulse sequencing (CPS) is a recently introduced, highly promising 
contrast-enhanced ultrasound imaging technology that uses nonlinear fundamental frequencies, 
resulting in improved spatial resolution and higher sensitivity to microbubble contrast media 
(Phillips and Gardner, 2004). Furthermore, CPS provides better tissue penetration, less attenuation, 
and more improved tissue subtraction than previous ultrasound perfusion imaging techniques 
(Phillips and Gardner, 2004). Importantly, CPS is technically less demanding, and the imaging 
protocol is much quicker than, for example, that of DCE-MRI. The properties of the most common 
imaging techniques are summarized in Table 2. 
 
Table 2. Comparison of the most typical imaging methods for imaging of the vasculature 
 Spatial 
resolution
Advantages Disadvantages
DCE-MRI ~100 m Contrast agent sensitivity, 
whole body scans possible, 
functional imaging possible. 
Expensive, poor availability, 
post processing needed and 
technically demanding. 
Micro-CT 10-100 m Good resolution, whole body 
scans possible. 
Low contrast sensitivity, 
radiation exposure, post 
mortem imaging, highly time 
consuming, poor availability 
and expensive. 
SPECT 5-6 mm Whole body imaging and 
molecular imaging possible. 
Expensive, radionuclides 
needed, laborious, poor 
availability, poor resolution, 
post processing needed. 
Laser Doppler ~1 cm Inexpensive, quick and easily 
available. 
Poor penetration (only ~1 
mm) and resolution. 
Power Doppler 
ultrasound
0.5 mm Inexpensive, quick and easily 
available, real-time imaging 
with high frame rates. 
Susceptible to movement 
artifacts, penetration limited 
to a few centimeters, limited 
sensitivity. 
CPS ultrasound 20-100 m Quick, real-time imaging 
with high frame rates, good 
tissue-contrast agent 
separation, high sensitivity. 
Contrast agent needed, still 
quite poorly available, 
penetration limited to a few 
centimeters. 
Modified from Miller et al 2005. DCE-MRI = dynamic contrast enhanced-magnetic resonance imaging, CT 
= computed tomography, SPECT = single photon emission computed tomography, CPS = contrast pulse 
sequence. 
 
30
   31 
AIMS OF THE STUDY 
 
The aim of this thesis was to study angiogenic gene therapy as a potential treatment for lower limb 
ischemia in animal models, as well as to elucidate factors involved in the growth of functional 
vessels and to compare methods suitable for imaging angiogenic vessels.    
 
The specific aims of this work were (according to each sub-study): 
 
I  To evaluate the arteriogenic potential of AdVEGF-A after an intra-muscular GT. 
 
II To test the feasibility of CPS ultrasound imaging in the assessment of angiogenesis. 
 
III To verify the functionality of vessels grown using gene therapy by studying the energetic 
reserve and exercise tolerance of ischemic muscles before and after AdPlGF GT. 
 
IV To study the potential of AdPDGF-B GT in the stabilization of vessels induced by a GT of 
AdVEGF-A.  
 
V To examine the effects of different AdVEGF-A doses on the induction of sprouting 
angiogenesis, capillary enlargement and formation of tissue edema, and to study the safety 
of efficient angiogenic gene therapy.   
 
VI To identify factors involved in the formation of endogenous collateral vessels in patients 
with peripheral arterial disease and chronic limb ischemia.  
MATERIALS AND METHODS 
 
Ischemia operations 
Two models of acute ischemia induced by a surgical operation have been used in this thesis work 
(Figure 7). Despite their limitations, surgically induced ischemia models are feasible approaches to 
study therapeutic angiogenesis as means for revascularization of ischemic tissues (Rissanen et al., 
2003a). Ligation of arteria femoralis profunda (PFA) was used in studies I and IV, and the ligation 
of arteria femoralis superficialis (SFA) (Rissanen et al., 2003a) in study III. The ligation of SFA 
was carried out according to previous description (Rissanen et al., 2003a) in the right hind limbs of 
New Zealand White rabbits a day before GT. Briefly, SFA and the re-entry branches for the 
collaterals growing from the lateral circumflex and deep femoral arteries were ligated under 
ketamine (Ketalar, Pfizer 0.3 ml/kg) and medetomidine (Domitor, Orion, 0.3 ml/kg) anesthesia. In 
this model the calf region is ischemic while the thigh remains normoperfused. The ligation of PFA 
was carried out under similar conditions but no re-entry branches for collaterals were closed. The 
GT was also performed immediately after the operation. In the PFA ligation model, the ischemia is 
much milder than that induced by the ligation of SFA, and is restricted to the adductor muscles 
making the model less painful for the animals. All animal experiments were approved by the 
Experimental Animal Committee at the University of Kuopio. 
 
 
 
Figure 7. Ischemia models used in the studies. 
Gene Transfer
GT was performed to New Zealand White rabbits (studies I-V) or 57Bl/6Ja mice (study II) either 
intra-muscularly (i.m., studies I-V) or intra-arterially (i.a., study V) under ketamine-medetomidine 
anesthesia in rabbits and ketamine (1,0mg/kg) -medetomidine (75mg/kg) anesthesia in mice. 
Human clinical grade, first generation, serotype 5, replication-deficient adenoviruses analyzed to be 
free from contaminants were used with viral doses ranging from 1x109 to 5x1011 vp/ml. Adenoviral 
human VEGF-A165, mouse PlGF-2 and human PDGF-B under the cytomegalovirus (CMV) 
promoter were used in different studies as described in Table 3. Adenoviral -galactosidase marker 
gene (LacZ) with the same promoter was used as a control in all studies. In rabbits 0.1 ml intra-
muscular injections were performed using a 1 ml syringe and a 25 G needle (studies I-V), and in 
mice 50 l injections with a 50 l Hamilton syringe and a 30 G needle (study II), respectively. In 
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rabbits, semimembranosus (10 injections), abductor cruris cranialis (8 inj.), quadriceps femoris (5 
inj.), tibialis anterior (3 inj.) or gastrocnemius (6-8 inj.) was injected as described in Table 3. In 
mice, one injection was performed in the inner thigh and one in the posterior calf (study II). In the 
intra-arterial GTs 1.0 ml of 5x1011 vp/ml AdLacZ or AdVEGF-A was injected through a butterfly 
needle selectively into the profound femoral artery while all arterial circulation into and from the 
transduced limb was closed. The virus was left to incubate in the circulation for 15 min after which 
the artery was flushed with 20 ml of NaCl and 15 ml of the lower limb venous return was drained 
via a 22 G cannula. After the operation, all vascular access points were sutured with 10.0 sutures 
restoring normal circulation. The effects of the GTs were studied six, 14 or 28 days after the GT as 
described in Table 3. 
 
Table 3. Summary of animal studies. 
Study
no
Animal
species 
Ischemia
operation 
Gene transfers Total 
doses
Transduced
muscles 
Time points
I Rabbit PFA    
ligation 
AdLacZ 
AdVEGF-A 
1011 vp Semimembranosus d6, d14 
II Rabbit, 
mouse 
- AdLacZ 
AdVEGF-A 
1011 vp Semimembranosus d6 
III Rabbit SFA 
ligation 
AdLacZ 
AdPlGF 
3x1011 
vp 
Semimembranosus, 
cruris cranialis, 
quadriceps femoris, 
tibialis anterior, 
gastrocnemius 
d6, d14, d28 
IV Rabbit PFA 
ligation 
AdLacZ 
AdVEGF-A 
AdPDGF-B 
AdV-A+ AdL-Z  
AdV-A+ AdP-B
1011 vp, 
2x1011 
vp for 
combi-
nations 
Semimembranosus d6, d14, d28 
V Rabbit - AdLacZ 
AdVEGF-A 
1.6x1011 
vp 
Semimembranosus, 
gastrocnemius 
d6, d14 
Assessment of skeletal muscle perfusion and blood volume  
  
 
Ultrasound imaging 
 
Three different ultrasound approaches have been used to assess skeletal muscle perfusion in the 
studies: Native Doppler (Studies I-V), Contrast enhanced Doppler (CEU, studies I and IV) and 
Contrast Pulse Sequence ultrasound (CPS, studies II, III and V). All ultrasound imaging was 
performed with Acuson Sequoia 512 system and 15L8 transducer (Siemens). For CEU and CPS 
applications a second generation contrast agent (sulfur hexafluoride in a phospholipid shell, approx. 
2x108 bubbles/ml, mean diameter 2.5 m, SonoVue, Bracco) was used. Native Doppler imaging 
was performed without contrast administration in both rabbits and in mice with the following 
parameters: 12.5 frames/s, power Doppler at 14 MHz, dynamic range 20 dB, power -5 dB, gain 50 
and depth 20 mm. For CEU in rabbits transversal plane video clips of 20 sec were captured using 
the power Doppler (mechanical index=0.6) mode at 8.5 MHz (dynamic range 10 dB, power -18 dB, 
mechanical index 0.60, gain 40 and depth 20 mm) with the administration of a 0.3 ml bolus of 
SonoVue via the ear vein. CPS imaging was performed in rabbits after an i.v. bolus injection of 0.5 
ml SonoVue with the following parameters at 8.0 MHz: power -16 dB, mechanical index 0.31, CPS 
gain -10 and depth 20 mm. In mice, 50 l of SonoVue was injected as a bolus with a Hamilton 
syringe and a 25 G needle via a silastic tube (diameter 1 mm) placed in the right external jugular 
vein under anesthesia. The following parameters were used for CPS imaging in mice: frequency 14 
MHz, power -8 dB, mechanical index 0.25, CPS gain -15 and depth 20 mm. Signal intensities (dB) 
of the ultrasound video clips were quantified with Datapro (v2.13, Noesis) and signal intensity-time 
curves were generated. Results are reported as ratios to intact values. 
 
  
Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) of rabbit thighs (studies I and II) was carried out in a 4.7 T 
magnet (Magnex, Abington, United Kingdom) interfaced to a Varian UNITYINOVA (Varian, Palo 
Alto, California) console with actively shielded gradients and with an in-house-built surface coil 
(diameter 38 mm). Dynamic contrast-enhanced (DCE)-MRI of perfusion with a FLASH pulse 
sequence (repetition time 9 ms, echo time 5 ms, field of view 6 x 6 cm2, resolution 64 x 64, slice 
thickness 5 mm, number of averages 1, acquisition time 0.58 s/image) was done after an i.v. 0.7 ml 
bolus injection of superparamagnetic iron oxide particles (Resovist, Schering; mean size 62 nm). 
The signal intensity–time curves were derived from the DCE-MRI data, and perfusion ratios were 
calculated. To obtain high-quality images of blood volume, T2*- weighted gradient echo images 
(repetition time 2 s, echo time 18 ms, field of view 6 x 6 cm2, resolution 256 x 128, slice thickness 
2.5 mm, and number of averages 2) were acquired before and 6 min after the bolus contrast agent 
injection to determine the steady-state distribution of the i.v. contrast agent. Finally, blood volume-
MRI maps (R2*) were reconstructed.
  
 
Microspheres 
Microsphere perfusion index between transduced semimembranosus muscles was measured at rest 
(study I) with red fluorescent microspheres (2x106, 15μm in diameter, FluoSpheres, Molecular 
Probes) injected into the left ventricle just before sacrifice (Pettersson et al., 2000; Rissanen et al., 
2003a; Krix et al., 2005). After sacrifice, microspheres were extracted from muscle samples with a 
sedimentation method according to the manufacturer’s instructions. The microsphere perfusion 
index was calculated as the ratio of red fluorescence between the transduced and contralateral intact 
semimembranosus muscles. Yellow-green microspheres were used as internal controls for pipeting 
errors. 
Assessment of skeletal muscle vascularity and structure of vessels 
 
  
Digital subtraction angiography 
To demonstrate collateral artery growth in ischemia operated rabbit hind limbs and the 
extravasation of X-ray contrast medium from growing VEGF-induced vessels (study I), selective 
digital subtraction angiography (DSA) was performed with a 4 F right coronary artery catheter 
(Cordis) introduced into the common carotid artery using a power-injection of 6 ml contrast 
medium (320 mg iodine/ml, Omnipaque, Amersham). Serial DSA images were recorded at the rate 
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of two images/s for 5 s (Siremobil 2000, Siemens), and the image representing the best arterial 
filling was chosen for analysis. 
 
 
Histological analysis 
 
Mean capillary area (m2) was measured, at 200x magnification, from CD31 immunostained 
sections obtained from areas covered entirely by skeletal muscle tissue (studies I, IV and V) 
(Rissanen et al., 2003b). All measurements were performed in a blinded manner from 10 fields 
representing maximal angiogenic effects of each muscle section using AnalySIS software (Soft 
Imaging System). To avoid ambiguous data caused from trauma effects of the needle injection, the 
analysis was made outside the needle track area. Means of the measurements were reported. Total 
area of arteries and veins (% of the total muscle area) was quantified from -sma stained sections at 
40x magnification covering the entire muscle (studies I, IV, V).  
 
The percentage of -sma positive pericytes, SMCs and myofibroblasts (% of the skeletal muscle 
area) were measured by immunofluorescence (FITC) of -sma-stained sections at 200x 
magnification (study IV). All measurements were performed, using AnalySIS software (Soft 
Imaging System), in a blinded manner from 5 fields that represented maximal -sma 
immunofluorescence of each muscle section. Measurements were taken from areas that did not 
contain large arteries or veins since their SMC layer could affect the results. 
Analysis of muscle energy metabolism 
  
 
31phosphorus -magnetic resonance spectroscopy (study III) 
The degree of ischemia and the level of aerobic metabolism (aerobic capacity) of rabbit calf 
muscles before the ischemia operation, and 6 and 28 days after GT were evaluated using 
31phosphorus -magnetic resonance spectroscopy (31P-MRS). 31P-MRS was performed with a 
UNITYINOVA imaging console (Varian) interfaced to a 4.7 T horizontal magnet (Magnex Scientific) 
with actively shielded gradients (Magnex Scientific). In-house built linear surface RF-coil 
consisting of two separate loops tuned to 1H and 31P frequencies with diameters of 38mm and 
25mm, respectively, were used for reception. Region of interest under the surface coil was shimmed 
using 1H signal and 31P data were acquired after ~70 degree hard pulse excitation using a repetition 
time of 1.5 s, spectral bandwidth of 10 kHz covered by 4096 data points and a number of averages 
of 16. Small needle electrodes (27 G) were placed on both sides of the sciatic nerve on the lateral 
side of the rabbit thigh. During the whole duration of the experiment (20 min) 31P-MRS spectra 
were collected each taking 30 s. First, resting spectra were collected for 2 min. Thereafter, the 
sciatic nerve was electrically stimulated for 6 min at 3 Hz using a voltage of 75-125 V (14A11 
Electromyograph, Disa) to induce maximal contractions in the calf muscles. Then, the stimulation 
was ceased and muscle recovery was followed for 12 min. JMRui 2.1 was used for line shape fitting 
analyses of the spectra after pre-processing the data by discarding the two first data points, using a 
DC correction of 500 and 15 Hz line broadening. The ratio between the peak areas of 
phosphocreatine (PCr) and the sum of PCr and inorganic phosphate (Pi) i.e. PCr/(PCr+Pi) was 
calculated and used as a measure of aerobic capacity and fatigue. Additionally, pH was derived 
from the chemical shift (placement on the peak on the x-axis) difference between PCr and Pi peaks.  
 
  
Arterial acid-base analysis (study V) 
 
For systemic acid-base balance and blood gas analysis 1 ml of arterial blood was collected into 
heparinized 1 ml syringes before and immediately after electrically stimulated exercise before, 6 
and 14 days after GT. The samples were immediately analyzed using an ABL625 analyzer 
(Radiometer Copenhagen) and blood gas concentrations, electrolyte values and metabolite values 
were recorded.    
Tissue edema and vascular permeability  
 
The Modified Miles assay was used in rabbits for the evaluation of tissue edema at sacrifice (studies 
I, III-V). Evans Blue dye (30 mg/kg, Sigma) was injected i.v. 30 min before sacrifice. After 
sacrifice, the animals were perfusion-fixed with 1 l of 1 % paraformaldehyde (PFA) in 0.05 M 
citrate buffer (pH 3.5) via the left ventricle. Extravasated Evans Blue dye bound to plasma was 
extracted from transduced and contralateral intact muscle samples by incubation in formamide at 60 
C for 48 h. The amount of extravasated Evans Blue dye was determined on the basis of absorbance 
at 610 nm (Rissanen et al., 2003b). The results are represented as absorbance ratios between the 
transduced and contralateral intact muscles. The absorbances were normalized to the weight of the 
muscle sample.  
Immunohistological and histological stainings 
After sacrifice, the animals were perfusion-fixed with 1 % paraformaldehyde in 0.05 M citrate 
buffer (pH 3.5) via the left ventricle. Sample tissues were then immersion-fixed in 4 % 
paraformaldehyde/ 15 % sucrose (pH 7.4) for 4 h, immersed in 15 % sucrose (pH 7.4) overnight 
(Rissanen et al., 2003b). Confocal microscopy samples (studies IV and V) were then frozen on dry 
side embedded in Tissuetech embedding medium. Samples for light microscopy (studies I-V) were 
embedded in paraffin. Samples for histochemical alkaline phosphatase (AP) and dipeptidyl 
peptidase IV (DPP) stainings (study I) were collected from non-fixed animals and the samples were 
immediately frozen in isopentane cooled down with liquid nitrogen.  
 
Avidin-biotin-HRP and alkaline-phosphatase systems (Vector Laboratories) with 3’-5’-
diaminobenzidine (DAB, Zymed) and Vector Blue (Vector) color substrates were used, 
respectively, for immunohistochemistry on 7 μm thick light microscopy sections. The range of 
antibodies used in immunostainings is described in Table 4. To visualize vessels that are perfused, 
Rhodamine-labeled Ricinus Communis lectin (1 mg in 10 ml of saline, Cat.# RL-1082, Vector) was 
injected into the common femoral artery using a 4 F catheter just before sacrifice in a subset of 
animals (study I, IV and V). Proliferation marker BrdU (20 mg/kg, Sigma) was given 3 h before 
sacrifice to detect proliferation (study I). Intra-arterially injected Rhodamine-labeled Ricinus 
Communis lectin and FITC-conjugates were used for immunocytochemistry on 50 m thick 
confocal sections. Controls for immunostainings included incubations with irrelevant class- and 
species-matched immunoglobulins and incubations in which the primary antibody was omitted 
(studies I-V).  
 
Alkaline phosphatase (AP) and di-peptityl-peptidase (DPP) activity on blood vessels was 
demonstrated by the azo-coupling method on frozen sections (study I) (Langille and O'Donnell, 
1986; Hansen-Smith et al., 1992; Saltin et al., 1998; Giatromanolaki et al., 2001; Giatromanolaki et 
al., 2002). Briefly, for the AP staining the sections were incubated in medium containing 10 mg of 
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Naphthol AS-BI phosphate (disodium salt, Sigma) dissolved in 0.5 ml of N,N-dimethylformamide 
(Aldrich) and 10 mg of Fast Blue BB Salt (Fluka) dissolved in 10 ml of veronal-acetate buffer (pH 
9.2) for 90 min. For the DPP staining the sections were incubated in Gly-Pro-4-- naphthylamide 
(Cat no G-9262, Sigma) at room temperature under microscopic control for 90 minutes.  
 
Photographs of the 7 m thick histological sections were taken with an Olympus AX70 microscope 
(Olympus Optical) and analySIS software (Soft Imaging System) (studies I-V). Fluorescent images 
were taken using an Olympus U-RFL-T burner (study I). Confocal images of the 50 m thick 
sections were taken with an Olympus IX81 microscope and a Fluoview-1000 confocal setup 
(studies IV and V). Reconstructions of the confocal images were done with an open source software 
package, BioImageXD. Images were further processed for publication with Adobe Photoshop 7.0 
(Adobe) (studies I-V).  
 
Table 4. Antibodies used in immunohistology. 
Antibody Specificity Clone/ 
Code
Manufacturer Dilution 
used
Pretreatment Used in 
studies
CD31 Endothelium JC/70A Dako 1:50 - I - V 
Griffonia 
simplifolia 
lectin I 
Endothelium B-1105 Vector 1:100 - II 
-sma Pericytes, 
smooth 
muscle 
1A4 Sigma 1:250 - I, IV 
VEGF VEGF121-206 c-1/         
Sc-7269 
Santa Cruz 1:500 citrate boiling I, IV, V 
PDGF-B PDGF-B AF-220-NA R&D 1:500 citrate boiling IV 
VEGFR-1 VEGFR-1 Sc-316 Santa Cruz 1:250 - IV 
VEGFR-2 VEGFR-2 MFLK1 RDI 1:250 citrate boiling IV 
PDGFR- PDGFR- Sc-6252 Santa Cruz 1:200 - IV 
-Gal -
galactosidase 
Z3783 Promega 1:500 - I, V 
BrdU Proliferating 
cells 
Bu20a Dako 1:100 BrdU injected I 
Ki67 Proliferating 
cells 
MIB-1 Dako 1:100 citrate boiling IV 
RAM11 Macrophages M0633 Dako 1:200 - IV 
RAM11 Macrophages M0633 Dako 1:200 trypsin V 
HAM56 Macrophages, 
monocytes 
M0632 Dako 1:500 trypsin  IV 
Desmin  D33 Sigma 1:100 - IV 
Vimentin  V9 Sigma 1:50 - IV 
Transgene expression 
  
 
mRNA expression analysis (study V) 
 
The localization of VEGF-A mRNA was shown by non-radioactive in situ hybridization (Roche 
Diagnostics Co., Mannheim, Germany) from paraffin sections using a digoxigenin- (DIG) labeled 
antisense and sense probes for VEGF-A according to previous description (Ylä-Herttuala et al., 
1991; Karvinen et al., 2009). Paraffin sections were pretreated with Proteinase K (Roche 
Diagnostics Co., Mannheim, Germany) (10 g/ml). Hybridization of slides was carried out in a 
hybridization buffer (40 % deionized formamide, 10 % dextran sulfate, 1 × Denhardt's solution, 4 × 
saline sodium citrate buffer (SSC), 10 mM ditiothreitol, 1 mg/ml yeast tRNA, 1 mg/ml denatured 
ssDNA) containing antisense or sense probes with the concentration of 0.33 ng/l overnight at 58 
°C. After hybridization the slides were washed in a shaking water bath at 58 °C with decreasing 
SCC concentration. Immunological detection of DIG-labeled probes was done according to the 
manufacturer's protocol (Roche Diagnostics Co., Mannheim, Germany) using anti-DIG-alkaline 
phosphatase Fab fragments (Roche Diagnostics Co., Mannheim, Germany). A color reaction was 
detected with Nitro blue tetrazolium chloride/ 5-Bromo-4-chloro-3-indolyl phosphate, toluidine salt 
(NTB/BCIP) solution (Roche Diagnostics Co., Mannheim, Germany).  
 
  
Protein expression analysis 
 
Muscle samples taken at sacrifice were frozen in liquid nitrogen and stored at -70 °C. T-Per buffer 
(Thermo Scientific) with 1x Halt protease inhibitor (Thermo Scientific) was used for protein 
extraction from homogenized muscle samples. The amount of protein in each sample was quantified 
with hVEGF-A (studies IV-V) and hPDGF-B (study IV) enzyme-linked-immuno-sorbent-assay kits 
(R&D Systems) and further normalized to the amount of total protein in each protein extract. The 
amount of total protein in each sample was quantified with BCA protein assay kit (Thermo 
Scientific). 
Assessment of gene therapy related side-effects 
  
 
Inflammatory cells 
 
Inflammatory responses induced by different adenoviral doses (study V) were measured from 
trypsin treated and RAM11 immunostained sections of semimembranosus muscles at 100x 
magnification. All measurements were performed in a blinded manner from 5 fields representing 
maximal staining of each muscle section using analySIS software (Soft Imaging System). To avoid 
confounding effect of the needle injection trauma the analyses were made outside the needle track 
area. Means of the measurements are reported. 
 
  
Clinical chemistry 
 
Arterial blood samples were collected from a subgroup of animals (study V) to 9 ml Z Serum Clot 
Activator Vacuette tubes (Greiner Bio-One) before, 6 and 14 days after GT. Serum was extracted 
from the samples and frozen to -70 C until analysis. Clinical chemistry including analysis of 
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kreatinin, inorganic phosphate, alanine aminotransferase, aspartate aminotransferase, amylase, C-
reactive protein, haptoglobin and alkaline phosphatase was performed in the Eastern-Finland 
laboratory centre (ISLab) in Kuopio University Hospital.  
  
 
Electrocardiography 
 
Electrocardiograms were registered using a 12 -lead electrocardiograph (Sicard 460, Siemens) in a 
subgroup of rabbits (study V) before, and 6 and 14 days after GT. Each electrocardiogram was 
analyzed systematically for heart rate, conduction, configuration, duration and amplitudes of 
different components.  
Analysis of collateral growth in CLI patients (study VI) 
 
  
Patient selection 
 
Preoperative angiograms and medical records for all patients (N=96) scheduled for femoropopliteal 
or femorodistal revascularization at the department of Vascular Surgery, Kuopio University 
Hospital, between January 2004 and December 2005 were retrospectively reviewed. Patients were 
included in the study when indication for surgery was claudication or chronic critical leg ischemia, 
due to occlusion of the superficial femoral artery (SFA) with open popliteal artery and at least one 
patent calf artery. Patients with a significant aortic stenosis or those who had previously been 
treated with ipsilateral surgical bypass reconstruction were excluded. Finally, 70 patients formed the 
study population. Demographic data, risk factors and co-morbidities were studied and recorded. The 
information on the disease onset, stage, duration of symptoms, functional capacity, claudication 
distance and ankle/brachial indexes (ABI) were registered.  
 
  
Angiographic findings 
 
A systematic quantification and qualification of collateral vessels bypassing the occluded SFA was 
performed. A re-elaboration of the angiograms was performed using digital subtraction angiography 
(DSA) workstation software (Sectra AB, Sweden), adjusting zoom, contrast and brightness 
parameters to visualize also the smallest collaterals. Image readings were done independently by 
two vascular surgeons blinded for patients’ medical history. In the assessment all arterial vessels 
bypassing a horizontal plane at the proximal, medial and inferior third of the obstructed SFA 
segment were registered. The quality and stenosis of the inflow vessels (the iliac - common femoral 
region), outflow vessels (the popliteal region) and the number of patent outflow arteries below the 
knee were recorded. In addition, the length of the SFA occlusion was measured. The mean 
difference and standard deviation in regard of collateral counts between the two readers were small 
(< 10 %). The collateral count was the highest and the difference between the counters was the 
smallest in the counting line crossing the inferior third of the obstructed femoral artery segment. 
The mean value of the readings on this line was used for analysis of each patient (Sorlie et al., 
1978). 
Statistical analysis 
 
Results are expressed as mean + standard error of mean (SEM). Statistical significance was 
evaluated using Kruskal-Wallis test followed by Mann-Whitney U-test where appropriate (studies I-
V) with non-parametric data. Differences in continuous and categorized variables were tested by 
unpaired t-test and one-way Anova, respectively (study VI). Correlation analyses were performed 
using Pearson’s test for continuously distributed variables (Studies I, II and VI) and by Spearman’s 
Rho correlation (studies I-V) test with categorized variables. P< 0.05 was considered statistically 
significant. If a risk factor predicted the number of collateral vessels in the univariate analysis 
(study VI) (P< 0.10) it was entered into regression analysis in order to assess the independent 
factors affecting collateral vessel formation. All statistical procedures were performed using SPSS 
software (SPSS Inc., Chicago, IL, USA).  
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RESULTS 
 
Imaging angiogenesis 
 
We compared five different imaging modalities in the assessment of vascular growth associated 
with gene therapy (studies I and II). To calculate a perfusion index in normal muscles transduced 
with AdVEGF-A or AdLacZ in all methods, the peak tracer signal intensities between the 
transduced and contralateral limbs were used. The perfusion indices calculated with the use of 
native power Doppler ultrasound, CEU, CPS or DSC-MRI were very similar after AdVEGF GT 
(20- to 27-fold). Importantly, the microsphere method likely underestimated perfusion (15-fold 
increase after AdVEGF-A, as potent angiogenic growth factors such as VEGF-A significantly 
enlarged capillary size (diameter >15 m) so that microspheres (15 m) could not be retained in 
them. With respect to the feasibility of the methods, DSC-MRI produced high-resolution images of 
both capillary level vessels and large arteries but it was hard and time-consuming to perform and 
required extensive post-processing of the images unlike the real-time ultrasound techniques. The 
ultrasound analyses also provided information on the structure and function of the vascular bed 
(Figure 8).  
 
 
Figure 8. Information obtained from the ultrasound intensity vs. time graph. a) Blood volume and flow can 
be derived from the ultrasound signal using a Gamma variate function. The time to arrival of the i.v. contrast 
agent describes peripheral vascular resistance. b) The shape of the curve reflects different vessel types in the 
vascular bed; the presence of large arteries and shunting produced a steep curve with a high peak intensity 
(such as with AdVEGF-A), whereas a normal vascular network with normal-sized capillaries yielded a flat 
curve (AdLacZ). c) Furthermore, after AdVEGF GT in limbs with ligated PFA, the peak intensity was lower 
and the shape of the curve was flatter, reflecting the absence of the large conducting artery.  
The Power Doppler CEU imaging was capable of detecting only the large (~100 m) vessels, 
whereas microcirculation was invisible (study I). On the contrary, CPS ultrasound had a high spatial 
resolution allowing the detection of perfusion throughout the vascular bed (study II). CPS was able 
to detect moving microbubbles in enlarged capillaries that were only 10 to 20 m in diameter. 
Blood flow in normal-sized capillaries colocalized with very low CPS signal, whereas blood flow in 
enlarged capillaries colocalized with high CPS signal. Due to high spatial resolution of CPS 
ultrasound we were also able to show that intramuscularly injected AdVEGF-A induced 
angiogenesis mainly in the surrounding adipose tissue rather than in the targeted skeletal muscle 
itself in mouse hind limbs. This finding was confirmed by histological staining of capillaries 
(Figure 9).  
 
 
Figure 9. Angiogenesis is mainly induced in the subcutaneous tissue of mice after intra-muscular AdVEGF-
A injection. a) Normal perfusion in AdLacZ transduced thigh muscles (muscle borders marked with white 
dotted line). b) Increased perfusion in AdVEGF-A transduced limbs (white parenthesis) but outside the 
muscle borders (white dotted line). c) Normal sized capillaries in AdLacZ transduced control muscles 
(brown). d) A few enlarged arterioles /venules in AdVEGF-A transduced hind limb muscles (arrows) and 
normal sized capillaries (arrowheads). e) Normal sized capillaries in AdLacZ transduced subcutaneous tissue 
(brown). f) Highly enlarged vascular structures in AdVEGF-A transduced subcutaneous tissue (brown). 
Erythrocytes are also visible in some of the vessels indicating functionality (asterisks).  Scale bars 100 m. 
 
 
Stimulation of vascular growth by gene therapy 
 
Intra-muscular adenoviral injection was found more effective than selective intra-arterial injection 
in stimulation of skeletal muscle angiogenesis in rabbits (study V) (Figure 10/1). Both target muscle 
transgene expression analysis and CPS perfusion analysis showed no effect with the intra-arterial 
approach while intra-muscular injections with much lower dose resulted in significant effects.  
 
Intra-muscular AdVEGF-A GT into rabbit hind limbs induced dose dependent growth of the whole 
vascular tree (studies V) (Figure 10/2), increased perfusion (Figure 10/3) (studies I-V) and reduced 
peripheral resistance (study I) at six days in both intact and ischemic muscles. Enhanced formation 
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of collateral arteries was detected in angiograms of AdVEGF-A transduced limbs as compared with 
AdLacZ transduced limbs (study I). Capillary size measured from CD31 immunostained muscle 
sections was increased dose-dependently up to 12- and 17-fold after AdVEGF-A in intact and 
ischemic muscles, respectively, as compared to AdLacZ controls (Study V).  
 
Figure 10. Four steps from gene transfer efficacy to vascular growth and metabolic benefits. 1) Sufficient 
transgene expression needs to be achieved in the transduced muscles to reach therapeutic effects. Intra-
muscular GT (i.m.) was more efficient than intra-arterial GT (i.a.). 2) Growth of the whole vascular tree 
needs to be stimulated. Arteries (arrowheads), veins (thick arrows) and capillaries (thin arrows) are enlarged 
after AdVEGF-A GT as compared to the AdLacZ control. 3) Functional vessels are needed to increase the 
perfusion of transduced muscles. Perfusion is very low in the resting AdLacZ transduced muscle 
(arrowhead). Perfusion is highly increased after AdVEGF-A GT. Also tissue edema and free fluid (asterisk) 
are visible. 4) Only if efficient vascular growth and perfusion are stimulated can metabolic benefits be 
expected. Efficient angiogenic gene therapy can improve muscle aerobic energy production, decrease lactate 
formation and formation of metabolic acidosis. *P<0.05, **P<0.01. 
With arterial and venous vasculature, there was a dose-dependent increase until 5x1010 vp/ml 
AdVEGF-A, but after that a plateau was detected in histological analysis. At maximum 11- and 5.5-
fold increases were detected after AdVEGF-A in arterial area in intact and ischemic muscles, 
respectively. In venous vascular area 8- and 14-fold increases were observed at maximum in intact 
and ischemic muscles, respectively. As a result of vascular growth, maximum of 29- and 14.8-fold 
increases in skeletal muscle perfusion in intact and ischemic muscles, respectively, were found with 
AdVEGF-A as compared to AdLacZ controls (study IV). Also, AdPlGF was found to significantly 
increase perfusion, 15.8- and 7.8-fold in intact and ischemic muscles, respectively (study III). 
Additionally, as the result of vascular enlargement the ultrasound contrast agent arrived ~2-fold 
faster in AdVEGF-A transduced muscles than AdLacZ transduced muscles, reflecting a significant 
reduction in peripheral vascular resistance (study I). 
 
31P-MRS was used to objectively assess muscle energy metabolism in rabbit hind limbs (study III). 
Decreased aerobic capacity (36%) was observed during electrically stimulated exercise in calf 
muscles of ischemic limbs compared to intact limbs one day after the ischemia operation. AdPlGF 
improved aerobic capacity of ischemic limbs 45% compared to AdLacZ controls six days after GT 
(Figure 10). Also, the formation of metabolic acidosis during exercise and histologically detected 
signs of ischemia, such as necrosis and inflammation, were reduced in AdPlGF transduced ischemic 
limbs as compared to AdLacZ control limbs. 28 days after GT, aerobic capacity had recovered 
completely also in the control AdLacZ animals, due to the formation of endogenous collateral 
arteries and thus no difference could be detected between AdPlGF, AdLacZ and intact limbs. No 
effect on phosphorus metabolism was detected with 31P-MRS after AdPlGF GT in normoxic limbs. 
However, the formation of metabolic acidosis was reduced also in normoxic AdPlGF transduced 
limbs compared to normoxic controls (Figure 10/4). Analysis of blood pH and lactate levels after 
electrically stimulated exercise of AdVEGF-A transduced limbs also displayed dose-dependent 
decreases in the formation of lactate and metabolic acidosis during exercise as compared to AdLacZ 
controls (Figure 10/4) (study V).  
 
 
Stimulation of physiological angiogenesis 
 
Local concentration of VEGF-A (Figure 11, a-b) was found to determine the type of angiogenesis in 
normoxic rabbit hind limbs six days after GT (study V). Whereas sprouting angiogenesis could be 
stimulated already with small AdVEGF-A doses, capillary enlargement was dose-dependently 
increased even with a 100-fold greater dose (Figure 12). Furthermore, in ischemic muscles blood 
flow (Figure 11, c-d) affected the type of angiogenesis and stimulated capillary arterialization 
(study I).  In PFA operated limbs the angiogenic response was more variable than in intact limbs, 
resulting in sprouting angiogenesis and formation of blood lacunae depending on low and high 
flow, respectively. Inflammation and paracrine growth factors secreted by inflammatory cells 
accumulating in transduced muscles may also have an effect on angiogenesis. The main response to 
AdPDGF-B transduction was, instead of angiogenesis, proliferation of cells in the muscle 
interstitium (study IV). Some of these cells were -sma positive pericytes and fibroblasts but a 
remarkable fraction consisted CD31-, HAM56- and RAM11-positive cells that strongly expressed 
VEGF-A in immunostainings. In the very close proximity of these accumulating cells, occasional 
capillary enlargement could be detected after AdPDGF-B GT. Also, the distribution of growth 
factors within the muscle strongly affected the type of angiogenesis (Figure 11, e-f). After an intra-
muscular adenoviral transduction many cell types including satellite cells, vascular endothelium, 
muscle fibers and fibroblasts in the muscle interstitium and in muscle fascias were found expressing 
transgene mRNA with in situ hybridization (study V). However, immunostainings demonstrated 
that most of the produced protein was localized in the muscle interstitium and at the borders of the 
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muscles, near the muscle fascias (studies IV and V). As a result, physiological, dose-dependent 
vessel growth was induced in the middle parts of the muscle where VEGF-A concentration was 
more uniform but large torturous hemangioma-like lacunae were formed near the muscle fascias 
having strongly immunostained VEGF-A deposits (study V). Also, after AdVEGF-A+AdPDGF-B 
combination GT the expression of PDGF-B in the muscle interstitium instead of vascular 
endothelium caused the detachment of pericytes from vascular structures and their migration 
towards the higher PDGF-B gradient in the muscle interstitium.  
 
  
Figure 11. Factors affecting the type of angiogenesis. Blood flow, local VEGF-A concentration and the 
placement of the transgene in the tissue were found to affect the type of angiogenesis induced at six days. a) 
With low VEGF-A concentrations sprouting angiogenesis was induced but enlargement was minimal 
(endothelium brown). b) With high VEGF-A concentrations sprouting was similar to that with lower 
concentrations but enlargement was dose-dependently increased. c) In the absence of flow, sprouting 
angiogenesis was induced (endothelium blue, pericytes brown, sprouts indicated by arrowheads) after 
AdVEGF-A GT. d) In the presence of flow aberrant lacunae like vascular structures were formed (asterisks 
indicate vascular lumina). e) AdVEGF-A alone could induce efficient pericyte (brown) recruitment 
(arrowheads) likely via shear stress mediated mechanisms. f) Over-expression of PDGF-B besides VEGF-A 
outside endothelial cells created improper PDGF-B gradients that led to detachment of pericytes from 
capillaries (arrows). Pericytes were abundantly detected in the muscle interstitium (arrowheads).  
 
AdVEGF-A transduction resulted in arterialization of capillary structures including the formation of 
pericyte coverage already 6 days after GT (studies I, III and IV). Also, AP (arterial capillary 
marker) and DPP (venous capillary marker) activity was decreased on endothelium of enlarged 
capillaries after AdVEGF-A GT, suggesting transformation toward arterioles (study I). However, 
this did not imply improved stability of the newly formed vessels as most of the enlarged capillaries 
in AdVEGF-A transduced muscles regressed by 14 days after GT (studies I, IV and V). A similar 
trend was observed also with perfusion in AdVEGF-A transduced muscles; after reaching the 
maximal increase at six days, perfusion decreased rapidly, reaching control levels at 2 weeks. 
Perfusion increases induced by AdPDGF-B and AdVEGF-A+AdPDGF-B were still visible 14 days 
after GT. In addition to the ultrasound findings, the analysis of CD31 stained muscle sections 14 
days after GT revealed that in AdPDGF-B and AdVEGF-A+AdPDGF-B transduced muscles large 
arteries and veins, and, to some extent capillaries, were still enlarged. Also, cell density was still 
increased in the muscle interstitium and often colocalized with persistent angiogenic vessels 
indicating a role of the inflammatory cells in the increased duration of changes. Importantly, also in 
AdVEGF-A treated animals, collateral arteries and the effects on arterioles and venules persisted for 
at least two weeks (studies I and V). 
 
 
Figure 12. Physiological vessel growth is desired after angiogenic gene therapy. Whereas high VEGF-A 
concentrations can induce aberrant vascular structures and severe plasma protein extravasation leading to 
tissue edema, lower VEGF-A concentrations yield physiological, less leaky vessels still having as high 
perfusion as the higher concentration six days after GT. a-c) Longitudinal confocal images of control (a) and 
angiogenic capillary vessels (b-c). d-f) Transverse light microscopy images of control (d) and angiogenic 
vessels (e-f). g-i) CPS ultrasound images of control (g) and AdVEGF-A transduced muscles (h-i). Free 
edematous fluid is visible between the AdVEGF-A transduced muscles (asterisks). j-l) Plasma protein 
extravasation (blue) as a mark of tissue edema after control (j) and AdVEGF-A GTs (k-l). Scale bars 50 m. 
 
Side-effects of angiogenic gene therapy 
 
Formation of tissue edema during angiogenesis was found to correlate best with the increase in 
capillary area, less with the increases in perfusion and arterial or venous vasculature, and not to 
correlate with capillary density (study V). Tissue edema could not be inhibited by a combination 
GT with AdVEGF-A and AdPDGF-B (study IV). Instead, even an increase in edema formation was 
observed in ischemic limbs transduced with AdVEGF-A+AdPDGF-B as compared to AdVEGF-A 
alone. Instead, by titration of the overall viral dose physiological vessel growth could be stimulated 
and tissue edema avoided by a GT of a single growth factor (Figure 12) (study V). The 
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heterogeneity of the angiogenic response due to uneven distribution of VEGF-A within the 
transduced muscle seemed not to have a large effect on edema formation.  
 
Dose-dependent increase in blood VEGF-A levels was observed six days after intra-muscular 
AdVEGF-A GT in rabbit hind limbs (Figure 13). As high as a 83-fold increase in blood VEGF-A 
was observed with the 1011 vp/ml AdVEGF-A dose as compared to the AdLacZ control with the 
same dose. Systemic side-effects including transient increases in liver, kidney and pancreatic 
enzymes, decrease in arterial blood pH, increase in blood lactate levels, and severe electrolyte 
changes, such as hyponatremia, hyperkalemia and hypocalsemia were detected six days after the 
1011 vp/ml AdVEGF-A GT. 1011 vp/ml AdLacZ control or AdVEGF-A with lower doses (109 or 
1010 vp/ml) had none of these effects. Analysis of electrocardiograms from animals that had 
received AdVEGF-A GTs revealed no dose dependent effects due to a high variation within the 
dose groups. However, when all the VEGF-A animals were pooled and compared to intacts and 
AdLacZ controls, significant effects on maximal R-wave amplitude and P-wave area could be 
detected, possibly indicating cardiac hypertrophy. In addition to the spread of the gene product 
through the systemic circulation, immunohistochemical analysis of lymph nodes six days after 
AdLacZ GT revealed that the transgene was expressed and widely distributed along the lymph node 
track after an intra-muscular GT (Figure 13). 
 
 
Figure 13. Both blood and 
lymphatic circulation serve as 
distributors of the transgene after an 
intra-muscular GT. a) Cells 
expressing -galactosidase 
(arrowheads) were found in the 
lymph nodes of AdLacZ transduced 
animals. b) Lymph nodes from 
normal animals showed no positivity. 
c) Blood VEGF-A levels were found 
to increase dose-dependently after 
intra-muscular AdVEGF-A GT. *P< 
0.05.
Factors affecting collateral growth (study VI) 
Hemodynamics were identified critical for collateral artery formation in patients with lower limb 
ischemia (Figure 14). In univariate analysis, the number of patent calf arteries was found to 
correlate with the collateral count (Pearson’s correlation 0.603, p<0.0001).  A correlation was also 
found between the collateral count and non-stenosed inflow arteries (Spearman’s Rho correlation 
0.304, p<0.05). Additionally, the presence of hypertension displayed an association with collateral 
count in variance analysis. Finally, in multivariate analysis only the quality of inflow and the 
number of patent calf vessels demonstrated an independent association (p<0.05) with the number of 
collaterals. Interestingly, the analysis revealed no relationship between low number of collaterals 
and a history of diabetes, chronic obstructive pulmonary disease, coronary artery disease, 
rheumatoid disease, renal disease, hypercholesterolemia, malignant disease or smoking. Age or the 
length of occlusion had also no effect of collateral formation. Supporting the role of hemodynamics, 
the number of collateral arteries was dramatically reduced after the studied patients had had surgical 
revascularization.  
 
Figure 14. Antegrade flow and peripheral 
runoff affect collateral formation. a-b) In the 
presence of poor antegrade flow and poor 
distal runoff very few functional collaterals 
are formed. c-d) In the presence of good 
antegrade flow and good distal runoff 
functional collaterals are formed. e-f) After a 
femoro-popliteal bypass operation (white 
transversal lines marking the bypass craft) 
formed collaterals regress.   
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DISCUSSION  
 
 
Tools for studying vascular growth 
  
As the effects of angiogenic gene therapy take place mostly at the capillary level vessels, imaging 
changes occurring in capillaries is crucial to demonstrate the efficacy of the treatment also in 
clinical trials (Rissanen and Yla-Herttuala, 2007). The assessment of changes taking place at the 
capillary level has been so far out of reach due to the lack of proper non-invasive imaging 
modalities for the capillary level vessels and the difficulty of obtaining histological biopsies. Digital 
subtraction angiography, CT-angiography or MRI approaches have been used to show changes in 
collateral vessels in clinical trials (Makinen et al., 2002) but the results from these trials are 
compromised by the lack of evidence of angiogenesis actually taking place. Additionally, strong 
vascular growth by AdVEGF-A involving manifold capillary enlargement and increased vascular 
permeability interferes with many standard vascular imaging and perfusion measurement techniques 
such as x-ray angiography and the microsphere method as shown in this study and, as shown 
previously, contrast-enhanced MRI with the use of low-molecular-weight extracellular contrast 
agents such as gadolinium (Rissanen et al., 2003a; Rissanen et al., 2003b). In these circumstances, 
the contrast agent must not extravasate and the method must not assume physiological capillary 
size. Contrast enhanced ultrasound imaging is very attractive for quantitative perfusion 
measurement after angiogenic therapies because it meets these requirements, is noninvasive, is 
approved for humans, provides quantitative data on blood flow kinetics, and enables 3D 
reconstruction of vasculature without nefrotoxic contrast agents or ionizing radiation (Krix et al., 
2005; Miller et al., 2005). 
 
Here it has been shown that by contrast enhanced ultrasound imaging changes at capillary level 
vasculature can be followed non-invasively with high correlation to histological evaluation of 
angiogenesis. Additionally, the ultrasound data can be used to obtain information about the function 
of the vascular bed e.g. peripheral resistance, types of vessels and shunting. Ultrasound imaging and 
especially CPS can also be utilized in animal models of angiogenesis. With CPS, a higher frequency 
(14 MHz) can be used in mice than in rabbits (8.5 MHz), owing to a smaller region of interest and a 
higher amount of contrast agent used in proportion to the body size, and thus the spatial resolution 
is even better in mice than in rabbits. Indeed, the accuracy of CPS imaging is very closely 
correlated to histological findings of angiogenesis reaching 10-20 m in spatial resolution with 14 
MHz. In contrast to imaging techniques such as Laser Doppler which penetrates only ~1 mm in the 
skin (Miller et al., 2005), ultrasound imaging also provides superior tissue penetration. For 
example, Laser Doppler could not have been able to differentiate between subcutaneous and 
skeletal muscle perfusion increases in our mouse hind limb model. CPS ultrasound is expected to be 
a valuable tool in the future trials of therapeutic angiogenesis.    
 
Besides imaging angiogenesis and perfusion, it is very important to actually measure the 
functionality of the induced vessels, as the measurement of perfusion alone does not always reflect 
the actual metabolic effects. In this study two methods have been used to evaluate the metabolic 
activity of the induced neovessels: 1) 31P-MRS in ischemic animals and 2) the measurement of acid-
base balance and lactate formation in unoperated animals. The measurement of lactate formation 
from arterial blood samples is a simple method suitable for experimental research in relatively large 
animals. However, it is affected by the distribution of the metabolites in the systemic circulation 
and thus may not be used reliably in ischemic tissues. In contrast, 31P-MRS, although more 
laborious, can be used to reliably study the energy metabolism of ischemic muscles (Isbell et al., 
2006). 31P-MRS is also feasible in clinical settings and can be used to objectively assess exercise 
tolerance of ischemic muscles unlike many of the current techniques, such as the treadmill test that 
is strongly dependent on the co-operation of the tested (Isbell et al., 2006). With these tools it was 
here demonstrated in a rabbit model that the neovessels induced by angiogenic gene therapy could 
improve the aerobic energy metabolism of ischemic muscles and decrease the formation of 
metabolic acidosis also in normoxic muscles. In the future, a similar demonstration of a functional 
benefit from ischemic human limbs would be needed in order to actually assess the benefits of 
angiogenic gene therapy in humans.  
 
 
Growing functional vasculature 
Vascular growth is a complicated process and regardless of whether it takes place in ischemic 
muscle or during embryonic development it is orchestrated by several different growth factors and 
their isoforms (Conway et al., 2001). The role of VEGFs in vascular growth, although essential, has 
mainly been considered to be the stimulation of endothelial cell proliferation, migration and the 
relaxation of the vascular wall allowing enlargement and sprouting of vessels (Ferrara, 2004). 
PDGFs on the other hand are regarded as the stimulators of smooth muscle and pericytes needed to 
build a stable vessel (Lindahl et al., 1997; Tallquist and Kazlauskas, 2004). Thus, the functionality 
of vessels grown by gene therapy with a single growth factor or growth factor isoform has been 
questioned (Whitlock et al., 2004; Pajusola et al., 2005) and several gene combination cocktails 
have been tested in order to create more physiological vessels (Richardson et al., 2001; Hao et al., 
2007). Here the combination of adenoviral VEGF-A and PDGF-B was tested with unexpected 
results. It was demonstrated that it is simply not enough to inject the growth factors into the target 
tissue but the growth factors need to be expressed in the right cell types. After an intra-muscular GT 
growth factor expression was shown to take place in several cell types. The secreted growth factor 
was also often bound to the extra cellular matrix with high quantities inducing high growth factor 
gradients towards the interstitium. After an intra-muscular injection AdVEGF-A alone could induce 
relatively efficient vascular growth and pericyte recruitment in the presence of efficient blood flow 
even if the transgene was not expressed in the vessel wall, likely due to blood flow and shear-stress 
mediated mechanisms. In contrast, the non-targeted expression of PDGF-B after an intra-muscular 
adenoviral injection appeared to cause, besides pericyte proliferation, detachment of pericytes from 
vessels, likely due to improper endothelial PDGF-B retention (Lindblom et al., 2003). When blood 
vessels dilate, blood flow and pressure are increased inside the vessels leading to increased shear 
stress on the vessel walls (Schaper and Scholz, 2003). Shear stress induces stimulation of pressure 
receptors that in response stimulate the production of several growth factors, including PDGFs, that 
induce changes in the vessel wall, such as attracting pericytes, to make it more resistant to the 
increased blood pressure (Schaper and Scholz, 2003). Thus, the expression of AdVEGF-A or 
another angiogenic growth factor alone can induce the growth of vessels having functional pericyte 
coverage (Dor et al., 2002) as it not only stimulates vascular growth but also starts a cascade of 
growth factor expression leading to the stabilization of the induced vessels.  
 
The functionality of newly formed vessels has often been linked to the structure of vessels. 
Sprouting angiogenesis has often been considered the more physiological type of angiogenesis after 
angiogenic GTs in comparison to capillary enlargement that has been associated to aberrant 
angiogenesis taking place in tumors (Dor et al., 2002; Ozawa et al., 2004). Especially angiopoietins 
have been implicated to have a role in the normalization of aberrant vessels induced by a VEGF-A 
GT (Davis et al., 1996; Thurston et al., 1999; Papapetropoulos et al., 2000; Hawighorst et al., 2002). 
However, the potential of sprouting angiogenesis without enlargement in revascularization of 
ischemic tissues is remarkably less than that with enlargement, as blood flow is greatly dependent 
on vascular diameter according to Poiseuille’s law (Guyton and Hall, 2000). Here in a AdVEGF-A 
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dose titration study it has been demonstrated that whereas high VEGF-A doses can induced the 
growth of torturous, hemangioma-like vessels, uniformly enlarged vessels can be induced by simply 
lowering the amount of AdVEGF-A. It was found that all the tested AdVEGF-A doses could 
stimulate sprouting angiogenesis whereas capillary enlargement and finally the formation aberrant 
lacunae required increasingly higher VEGF-A levels. Interestingly, the functionality of the vessels 
formed after AdVEGF-A GT, measured by improved aerobic energy production, was found to 
increase dose-dependently along with the increase in capillary area, even with the highest doses. 
With the lowest AdVEGF-A dose tested (109 vp/ml) sprouting angiogenesis was induced with the 
same magnitude as with the higher doses but capillary enlargement was very minimal. With this 
dose no effect on muscle energy metabolism was detected indicating that there is a threshold in 
angiogenesis, namely on capillary enlargement, before effects on muscle energy metabolism can be 
detected.   
 
Capillary enlargement as a form of angiogenesis after angiogenic gene therapy is still often not 
recognized. As shown here, capillary sprouting can be stimulated already with very low VEGF-A 
doses, where as capillary enlargement requires higher VEGF-A doses and sufficient blood flow. A 
large portion of gene therapy studies, to date, have still been conducted with plasmids and 
recombinant proteins leading to relatively low levels of growth factors in target tissues. Also, 
growth factors and viral vectors vary in their efficacy of promoting angiogenesis depending on their 
biological activity and modifications. Furthermore, the most used animal model in angiogenic gene 
therapy is mouse and as shown here, the efficacy of angiogenic gene therapy with adenoviral 
vectors is much lower in mouse skeletal muscle than that with rabbit skeletal muscle or mouse 
subcutaneous tissue, possibly due to differences in vector or growth factor related receptors. Thus, 
the significance of capillary enlargement may still be unclear to many researchers due to the fact 
that they have not seen it in their studies. These differences in models and GT tools create a great 
variability in determining what is efficient angiogenesis and may also have led to the use of 
ineffective gene products in clinical trials, explaining the lack of positive results (Rissanen and Yla-
Herttuala, 2007). Based on the results presented here, the efficacy of angiogenic gene therapy 
should not only be based on the level of sprouting angiogenesis induced but the level of capillary 
enlargement should also be evaluated - especially as the beneficial effects on muscle energy 
metabolism seemed to be highly correlated to the level of capillary enlargement and not on 
sprouting angiogenesis.   
The efficacy of gene therapy is also highly related to the method of gene delivery, especially in 
regards to the injection site (Yla-Herttuala and Alitalo, 2003). An intra-vascular GT has appeal as 
for its ability to spread the virus to large areas. However, it obviously then can also easily transduce 
Figure 15. A summary of 
steps essential for efficient 
angiogenic gene therapy.  
unwanted tissues and could, in theory, result in acceleration of tumor growth for example (Hiltunen 
et al., 2000). Additionally, in regard of ischemic tissues the gene product would not actually reach 
the ischemic areas as by definition the ischemic areas are void of circulation (Rissanen and Yla-
Herttuala, 2007). Gene transfer efficacy after an intra-vascular administration is also hampered by 
endonucleases and efficient immune responses neutralizing circulating vectors quickly, as well as 
constant blood flow that would make it hard for the vector to attach to vascular endothelium and 
enter endothelial cells (Guyton and Hall, 2000). Here it was demonstrated that although much 
higher adenoviral doses would be used in selective intra-arterial administration than in intra-
muscular administration, the efficacy of the intra-vascular approach is questionable. A summary of 
proposed steps needed for efficient angiogenic gene therapy are presented in Figure 15. 
Duration of angiogenic changes 
 
To gain a true clinically relevant angiogenic response, the vessels induced by gene therapy need to 
be stable and functional for long periods of time. Adenoviral vectors induce transient but very high 
expression of the encoded growth factor but due to the nature of the virus the expression is quickly 
shut down after about two weeks (Muruve, 2004; Korpisalo P et al., 2007). With AdVEGF-A this 
means that a highly efficient angiogenic stimulus is first achieved but most of the angiogenic 
changes do not persist beyond the cessation of the growth factor expression at two weeks. The 
maturity of the vessel wall structure has been suggested to determine the stability of vessels after 
gene therapy (Benjamin et al., 1998; Conway et al., 2001). A four week expression of VEGF-A has 
been described to produce vessel structures stabile enough to resist regression after VEGF-A 
withdrawal (Dor et al., 2002). Thus, long expression vectors such as adeno-associated viruses 
(AAV) have been suggested more suitable for angiogenic gene therapy than adenoviruses (Dor et 
al., 2002; Yla-Herttuala et al., 2007). Here, an increase in the duration of adenovirally induced 
angiogenesis was desired and a combination GT of AdPDGF-B and AdVEGF-A stimulating both 
endothelial cells and pericytes was used in order to gain more mature vessels. As a result, an 
increase in the duration of angiogenesis was obtained after AdPDGF-B GT alone or in combination 
with AdVEGF-A. However, this increase was most likely not related to improved structure of 
vessels but rather mediated by paracrine secretion of growth factors from cells that had accumulated 
into the transduced muscles. The beneficial role of these, possibly bone marrow derived precursors 
or inflammatory cells and paracrine growth factors on vascular growth and stabilization after 
AdVEGF-A GT could have therapeutic implications but requires further research and development 
(Rehman et al., 2003; Kastrup et al., 2006).  
 
The level of perfusion in resting skeletal muscle is very low (Guyton and Hall, 2000). It is only 
natural that a balance in the amount of blood vessels is maintained at a level responding to the need 
of the tissue (Risau, 1997; Guyton and Hall, 2000). By gene therapy an overload of vasculature can 
be stimulated even in ischemic muscle. Here it has been shown that collateral vessels induced by 
AdVEGF-A GT as well as changes in arterial and venous vascular area remained elevated after the 
expression of adenovirus ended and most of the changes in capillary level vessels returned to 
baseline, in line with previously published results (Vajanto et al., 2002; Rissanen et al., 2003a). This 
might imply that vessels that are truly needed and are continuously perfused will survive even after 
just a short initial boost of growth factors, possibly due to blood flow and shear stress mediated up-
regulation of growth factors in the blood vessel endothelium (Vajanto et al., 2002). This theory is 
hard to test in practice as chronic ischemia, lasting over two weeks has been difficult to achieve in 
animal models so far. However, promising results have been published concerning gene transfers 
done before the ischemia operation that report improved recovery from acute ischemia after the 
expression boost of growth factor has passed (Gowdak et al., 2000).  
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Side-effects of angiogenic gene therapy 
In general, only mild side-effects have been reported to have occurred in clinical angiogenic gene 
therapy trials (Makinen et al., 2002; Rajagopalan et al., 2002; Yla-Herttuala et al., 2007). Besides 
mild immune reactions such as fever, one death associated with an overdose of adenovirus has been 
reported in an immunoincompetent patient (Lehrman, 1999). However, side-effects related 
especially to growth factors and efficient angiogenesis, besides moderate edema, have been more 
rarely described likely due to low efficacy of the clinical trials so far (Baumgartner et al., 2000; 
Rajagopalan et al., 2002). A common feature of the clinical trial protocols that might also have 
reduce the observation of side-effects is that the patients are not monitored at early time points (< 
one week) after the GT (Rajagopalan et al., 2002). As shown here the highest prevalence of side-
effects when using adenoviral vectors is around one week after the GT and most of the side-effects 
are diminished by two weeks. High circulating levels of VEGF-A were shown to induce liver, 
kidney and pancreatic effects. Additionally, cardiac changes were observed and could be in theory 
related to both the circulating VEGF-A or hemodynamic changes. Tissue edema was shown to 
develop dose-dependently after an angiogenic GT and to correlate with the level of capillary 
enlargement. While tissue edema can be largely avoided by the titration of the overall viral dose, as 
shown here, at the same time a compromise has to be made in the level of angiogenesis. It is also 
possible that increased perfusion and vascular permeability associated with efficient angiogenesis in 
the transduced muscles facilitates the release of the growth factor into the systemic circulation. 
Also, the lymphatic system was here shown to be a route for growth factor biodistribution. Thus, as 
the trials are constantly aiming towards better efficiency and using more powerful vectors than 
before, it can be assumed that the prevalence of angiogenesis-related side-effects will be increasing 
in future trials before optimal growth factor levels have been established. The safety data here 
demonstrates that subjects receiving gene therapy with adenoviral vectors, inducing high transient 
doses of growth factors and efficient angiogenesis, need to be observed carefully for the first two 
weeks after GT so that the side-effects can be recognized, and with optimization of the viral dose 
avoided in future trials.  
The potential of gene therapy in revascularization of ischemic tissues  
 
By natural repair, blood flow through collateral vessels compensates reduced blood flow through 
stenotic and occluded arteries (Schaper and Scholz, 2003). The degree of collateralization after an 
arterial occlusion has been suggested to be related to several factors, such as duration and level of 
ischemia, diabetes and pulmonary obstructive disease (Wahlberg, 2003; De Vivo et al., 2005; 
Topsakal et al., 2005). Our results from CLI patients indicate that while several factors, such as 
hypertension, may partially affect collateral vessel formation, only efficient antegrade flow and the 
functionality of vessels distal to the occlusion have an independent association on collateral vessel 
formation. Similarly to collateral formation and patency the success of radiological and surgical 
revascularization is dependent on these hemodynamic factors. As the hemodynamic factors 
mediating collateral formation upstream to an occlusion are often sufficient, the functionality of the 
runoff vessels remains a significant clinical problem. Angiogenic gene therapy could provide a 
precise treatment for opening up the distal vascular network and to improve the distal runoff in 
ischemic tissues. Here it has been shown in animal models that with angiogenic gene therapy it is 
possible to stimulate the growth of the whole vascular tree, increase skeletal muscle perfusion 
manifold, increase the level of aerobic metabolism in ischemic muscle and to reduce ischemic 
changes. Angiogenic gene therapy could be used not only as a single treatment but as an adjuvant 
therapy to surgical bypass and percutaneous revascularization operations to improve the runoff from 
crafts, maintain higher blood flow and pressure in stents or crafts and thus help to avoid restenosis.  
SUMMARY AND CONCLUSIONS 
 
In summary, the main findings of this work were (according to each sub-study): 
 
I  AdVEGF-A induces arteriogenesis, capillary arterialization and a decrease in peripheral 
resistance after an intra-muscular GT to rabbit hind limbs. Furthermore, blood flow 
modulates vascular growth in ischemic tissues.   
 
II CPS ultrasound imaging is feasible in the assessment of angiogenesis and could be used to 
evaluate capillary level vascular growth non-invasively with almost histological precision in 
both animal models and clinical trials. 
 
III Vessels grown with AdPlGF GT are metabolically functional as verified by studying the 
energetic reserves of ischemic rabbit muscles with 31P-MRS. AdPlGF GT results in a 
decrease in metabolic acidosis during exercise and decreases the amount of ischemic 
changes such as necrosis or inflammation in transduced muscles. 31P-MRS is feasible in the 
objective assessment of muscle energy metabolism and could also be used in clinical trials.  
 
IV Non-targeted intra-muscular AdPDGF-B induces detachment of pericytes from vessels 
when delivered in combination with AdVEGF-A likely due to formation of improper 
PDGF-B gradients. An increase in the duration of angiogenic changes observed after the 
AdPDGF-B GT is due to paracrine secretion of VEGF-A from recruited mononuclear cells 
rather than improved vascular maturity.  
 
V The dose of AdVEGF-A determines between sprouting angiogenesis and capillary 
enlargement. There seems to be a threshold with capillary enlargement after which 
metabolic benefits are induced. Additionally, by titration of the viral dose the formation of 
physiological vessels without major side-effects can be induced. The side-effects of 
angiogenic gene therapy are the most prominent one week after adenoviral transduction and 
are mediated by the spread of the growth factor via both blood and lymphatic routes.  
 
VI Hemodynamics, mainly the functionality of inflow and outflow vessels, determine the level 
of endogenous collateral vessel formation in patients with limb ischemia. 
 
This thesis project describes factors mediating endogenous collateral vessel formation in humans 
and presents means for induction of functional neovascular growth via angiogenic gene therapy in 
animal models. The potential of angiogenic gene therapy in supporting endogenous collateral 
formation has been extensively verified as regards to the functionality and structure of induced 
vessels. Additionally, novel methods, suitable for both preclinical and clinical use, have also been 
tested for imaging microvascular growth and studying the functionality of vessels induced by 
angiogenic gene therapy. It is concluded that therapeutic angiogenesis is a promising new treatment 
option for patients with severe peripheral vascular disease.   
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